COMPOSIÇÕES, MÉTODOS PARA MODIFICAR UMA POPULAÇÃO DE CÉLULAS E PARA TRATAR UMA BETA-HEMOGLOBINOPATIA E POPULAÇÃO DE CÉLULAS

The use of dCas9-Clo051 fusion proteins and targeted guide RNAs in lipid nanoparticles addresses the inefficiencies of current genome editing for hemoglobinopathies, enhancing fetal hemoglobin expression and providing a promising therapeutic approach.

BR112025024788A2Pending Publication Date: 2026-11-10POSEIDA THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
BR112025024788
Authority / Receiving Office
BR · BR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-17
Filing Date
2024-05-16
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Current genome editing technologies for treating hemoglobinopathies like sickle cell anemia and beta-thalassemia are limited by random insertion sites and inefficiencies in inducing fetal hemoglobin expression, leading to suboptimal therapeutic outcomes and safety concerns with existing treatments.

Method used

A composition comprising fusion proteins (dCas9-Clo051) and guide RNAs targeting specific sequences in the HBG1, HBG2, and BCL11A genes, encapsulated in lipid nanoparticles, to induce precise genomic modifications and enhance fetal hemoglobin expression.

Benefits of technology

The method achieves a significant increase in fetal hemoglobin production, up to 4-9-fold, in hematopoietic stem cells, potentially offering a more effective and safer treatment for hemoglobinopathies.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Disclosed are methods and compositions for functional genetic modifications at selected genomic sites such as BCL11A gene, HMG1 promoter and / or HMG2 promoter. Also provided are cell populations, which comprise the functional genetic modification at one or more selected gene loci.
Need to check novelty before this filing date? Find Prior Art

Description

1 / 97 “COMPOSITIONS, METHODS FOR MODIFYING A CELL POPULATION AND FOR TREATING A BETA-HEMOGLOBINOPATHY AND CELL POPULATION” Cross-reference to related orders

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 502,903, filed May 17, 2023, which is incorporated herein by reference in its entirety. Dissemination Field

[0002] This disclosure is directed to the field of gene editing and genomic engineering. More particularly, this disclosure is directed to compositions and methods for genetic modification that target and modulate the expression of a target nucleic acid sequence and applications thereof. Embedding by Reference of the Sequence Listing

[0003] This application contains a Sequence Listing that was submitted in XML format via the Patent Office and is incorporated herein by reference in its entirety. The said XML copy, created on May 8, 2024, is named “POTH085_001WO_SeqList_ST26.xml” and is 61,664 bytes in size. Background to the Disclosure

[0004] Genome editing refers to strategies and techniques for targeted and specific modification of the genetic information (genome) of living organisms. Genomic engineering is an active field of research due to the wide range of possible applications, particularly in the area of ​​human health, for example, to correct a gene carrying a harmful mutation or to explore the function of a gene. Previous technologies developed to insert a transgene into a living cell were often limited by the random nature of the insertion site of the new gene. Petition 870250103694, dated 12 / 11 / 2025, pp. 99 / 211 2 / 97 sequence in the genome. Common genome editing strategies allow a specific area of ​​DNA to be modified, thus increasing the precision of the correction or insertion compared to previous technologies. Although these platforms offer a higher degree of reproducibility and a lower level of undesirable effects from random insertions and deletions in the genome, limitations remain.

[0005] Hemoglobin (Hb) carries oxygen in erythrocytes or red blood cells (RBCs) from the lungs to the tissues. During prenatal development and until shortly after birth, hemoglobin is present in the form of fetal hemoglobin (HbF), a tetrameric protein composed of two alpha (α) globin chains and two gamma (γ) globin chains. HbF is largely replaced by adult hemoglobin (HbA), a tetrameric protein in which the γ globin chains of HbF are replaced by beta (β) globin chains, through a process known as globin exchange. The average adult produces less than 1% HbF of total hemoglobin.The hemoglobin-α gene is located on chromosome 16, while the hemoglobin-β (HBB) gene, the gamma globin chain A (γA) (HBG1, also known as gamma globin A), and the gamma globin chain G (γG) (HBG2, also known as gamma globin G) are located on chromosome 11, within the globin gene cluster (also known as the globin locus).

[0006] Mutations in HBB can cause hemoglobin disorders (i.e., hemoglobinopathies), including sickle cell anemia (SCD) and beta-thalassemia (β-Thal). Approximately 93,000 people in the United States are diagnosed with hemoglobinopathy. Worldwide, 300,000 children are born with hemoglobinopathies each year. Because these conditions are associated with mutations in HBB, their symptoms typically do not manifest until after the globin switch from HbF to HbA. Petition 870250103694, dated 12 / 11 / 2025, pages 100 / 211 3 / 97

[0007] SCD is the most common inherited hematological disease in the United States, affecting approximately 80,000 people (Brousseau, 2010). SCD is more common in people of African descent, for whom the prevalence of SCD is 1 in 500. In Africa, the prevalence of SCD is 15 million. SCD is also more common in people of Indian, Saudi, and Mediterranean descent. In descendants of Hispanic Americans, the prevalence of sickle cell anemia is 1 in 1,000.

[0008] Sickle cell disease (SCD) is caused by a single homozygous mutation in the HBB gene, c.17A>T (HbS mutation). The sickle cell mutation is a point mutation (GAG>GTG) in HBB that results in the substitution of valine for glutamic acid at amino acid position 6 in exon 1. Valine at position 6 of the hemoglobin-β chain is hydrophobic and causes a conformational change in the β-globin protein when not bound to oxygen. This conformational change causes HbS proteins to polymerize in the absence of oxygen, leading to deformation (i.e., sickling) of the RBCs. SCD is inherited in an autosomal recessive manner, so only patients with two HbS alleles have the disease. Heterozygous individuals have the sickle cell trait and may suffer from anemia and / or painful crises if severely dehydrated or oxygen-deprived.

[0009] Sickle cell RBCs cause multiple symptoms, including anemia, sickle cell crises, vaso-occlusive crises, aplastic crises, and acute chest syndrome. Sickle cell RBCs are less elastic than wild-type RBCs and therefore cannot pass through capillary beds as easily, causing occlusion and ischemia (i.e., vaso-occlusion). A vaso-occlusive crisis occurs when sickle cells obstruct blood flow in the capillary bed of an organ, leading to pain, ischemia, and necrosis. These episodes typically last 5 to 7 days. The spleen plays a role in eliminating dysfunctional RBCs and is therefore typically enlarged during the first Petition 870250103694, dated 12 / 11 / 2025, pp. 101 / 211 4 / 97 childhood and subjected to frequent vaso-occlusive crises. By the end of childhood, the spleen of patients with SCD frequently suffers infarction, leading to autosplenectomy. Hemolysis is a constant feature of SCD and causes anemia. Sickle cells have a lifespan of 10 to 20 days in circulation, while healthy RBCs have a lifespan of 90 to 120 days. Individuals with SCD receive transfusions as needed to maintain adequate hemoglobin levels. Frequent transfusions put individuals at risk of HIV, hepatitis B, and hepatitis C infection. Individuals may also suffer acute chest crises and infarctions of extremities, end organs, and the central nervous system.

[00010] Individuals with SCD have a reduced life expectancy. The prognosis for patients with SCD is steadily improving with careful, lifelong management of crises and anemia. In 2001, the average life expectancy for individuals with sickle cell anemia was in their mid- to late 50s. Current treatments for SCD involve hydration and pain management during crises, and transfusions as needed to correct anemia.

[00011] Thalassemias (e.g., β-Thal, δ-Thal, and β / δ-Thal) cause chronic anemia. It is estimated that β-thalassemia affects approximately 1 in 100,000 people worldwide. Its prevalence is higher in certain populations, including those of European descent, where its prevalence is approximately 1 in 10,000. β-thalassemia major, the most severe form of the disease, is life-threatening unless treated with lifelong blood transfusions and chelation therapy. In the United States, there are approximately 3,000 individuals with β-thalassemia major. β-thalassemia intermedia does not require blood transfusions but can cause growth retardation and significant systemic abnormalities, and often requires lifelong chelation therapy. Petition 870250103694, dated 12 / 11 / 2025, pp. 102 / 211 5 / 97

[00012] Beta-thalassemia is caused by mutations in the HBB gene. The most common HBB mutations that lead to beta-thalassemia are: c.-136C>G, c.92+1G>A, c.92+6T>C, c.93-21G>A, c.118C>T, c.316-106C>G, c.25_26delAA, c.27_28insG, c.92+5G>C, c.118C>T, c.135delC, c.315+1G>A, c.-78A>G, c.52A>T, c.59A>G, c.92+5G>C, c.124_127delTTCT, c.316-197C>T, c.-78A>G, c.52A>T, c.124_127delTTCT, c.316-197C>T, c.-138C>T, c.-79A>G, c.92+5G>C, c.75T>A, c.316-2A>G, and c.316-2A>C. These and other mutations associated with β-thalassemia cause mutated or absent β-globin chains, which disrupts the normal ratio between hemoglobin-α and hemoglobin-β. The excess α-globin chains precipitate into erythroid precursors in the bone marrow.

[00013] In β-thalassemia major, both HBB alleles contain nonsense, frameshift, or splicing mutations that lead to the complete absence of β-globin production (designated β0 / β0). β-thalassemia major results in a severe reduction in β-globin chains, leading to significant precipitation of α-globin chains in RBCs and more severe anemia.

[00014] Intermediate β-thalassemia results from mutations in the 5' or 3' untranslated region of HBB, mutations in the promoter region or in the polyadenylation signal of HBB, or splicing mutations in the HBB gene. Patient genotypes are designated as βo / β+ or β+ / β+. βo represents the absence of expression of a β-globin chain; β+ represents a dysfunctional but present β-globin chain. Phenotypic expression varies among patients. Because there is some β-globin production, intermediate β-thalassemia results in less precipitation of α-globin chains in erythroid precursors and less severe anemia than major β-thalassemia. However, there are more significant consequences of erythroid lineage expansion secondary to chronic anemia.

[00015] Individuals with β-thalassemia major present Petition 870250103694, dated 12 / 11 / 2025, pp. 103 / 211 6 / 97 symptoms appear between the ages of 6 months and 2 years and include growth retardation, fevers, hepatosplenomegaly, and diarrhea. Appropriate treatment includes regular transfusions. Therapy for β-thalassemia major also includes splenectomy and treatment with hydroxyurea. If patients are regularly transfused, they will develop normally until the beginning of their second decade. At that time, they require chelation therapy (in addition to ongoing transfusions) to prevent complications from iron overload. Iron overload can manifest as growth retardation or delayed sexual maturation. In adulthood, inadequate chelation therapy can lead to cardiomyopathy, cardiac arrhythmias, hepatic fibrosis and / or cirrhosis, diabetes, thyroid and parathyroid abnormalities, thrombosis, and osteoporosis. Frequent transfusions also put individuals at risk of HIV, hepatitis B, and hepatitis C infection.

[00016] Individuals with intermediate β-thalassemia typically present with symptoms between 2 and 6 years of age. They generally do not require blood transfusions. However, bone abnormalities occur due to chronic hypertrophy of the erythroid lineage to compensate for chronic anemia. Individuals may present with fractures of long bones due to osteoporosis. Extramedullary erythropoiesis is common and leads to enlargement of the spleen, liver, and lymph nodes. It can also cause spinal cord compression and neurological problems. Individuals also suffer from ulcers in the lower extremities and have an increased risk of thrombotic events, including stroke, pulmonary embolism, and deep vein thrombosis. Treatment for intermediate β-thalassemia includes splenectomy, folic acid supplementation, hydroxyurea therapy, and radiotherapy for extramedullary masses. Chelation therapy is used in individuals who develop iron overload.

[00017] Life expectancy is often reduced by Petition 870250103694, dated 12 / 11 / 2025, pp. 104 / 211 7 / 97 patients with β-thalassemia. Individuals with β-thalassemia major who do not receive transfusion therapy usually die in their second or third decade of life. Individuals with β-thalassemia major who receive regular transfusions and appropriate chelation therapy may live into their fifth decade of life and beyond. Heart failure secondary to iron toxicity is the leading cause of death in individuals with β-thalassemia major due to iron toxicity.

[00018] A variety of novel treatments are currently under development for SCD and β-Thal. Delivery of an anti-sickling HBB gene via gene therapy is being investigated in clinical trials. However, the long-term efficacy and safety of this approach are unknown. Transplantation with hematopoietic stem cells (HSCs) from an HLA-matched allogeneic stem cell donor has been shown to cure SCD and β-Thal, but this procedure involves risks, including those associated with ablation therapy, which is necessary to prepare the individual for transplantation, increases the risk of life-threatening opportunistic infections, and the risk of graft-versus-host disease after transplantation. Furthermore, matched allogeneic donors often cannot be identified. Reactivation of HBG gene expression (HBG1, HBG2) and induction of fetal hemoglobin (HbF) are important therapeutic strategies to improve clinical symptoms and severity of SCD.Hydroxyurea is the only drug approved by the US FDA with proven efficacy in inducing HbF in patients with SCD, although serious complications have been associated with its use. Over the past three decades, several additional pharmacological agents that reactivate HBG transcription in vitro have been investigated, but few have obtained FDA approval, with the exception of arginine butyrate and decitabine; however, none of these drugs have met the requirements for routine clinical use due to difficulties with oral delivery and the inability to... Petition 870250103694, dated 12 / 11 / 2025, pp. 105 / 211 8 / 97 reach therapeutic levels. Consequently, there is a need for improved therapeutic compositions and methods for the treatment of these hemoglobinopathies. There is a need to develop gene-editing platforms with superior efficacy in genome editing for the treatment of these hemoglobinopathies. Brief Description

[00019] The disclosure provides a composition comprising: a) a first guide RNA (gRNA) and a first fusion protein or a first polynucleotide encoding the first fusion protein comprising: a mutant Cas9 polypeptide (dCas9) or an inactivated nuclease domain thereof and a Clo051 polypeptide or a nuclease domain thereof, configured to form a complex with the first gRNA, and b) a second gRNA and a second fusion protein or a second polynucleotide encoding the second fusion protein comprising: a dCas9 polypeptide or an inactivated nuclease domain thereof and a Clo051 polypeptide or a nuclease domain thereof, configured to form a complex with the second gRNA, wherein i) the first gRNA comprises a first target sequence comprising a nucleotide sequence selected from SEQ ID NOs: 1, 5, 7, 13, 15 or 17;and the second gRNA comprises a second target sequence comprising a nucleotide sequence of SEQ ID NO: 3, or ii) the first gRNA comprises a first target sequence comprising a nucleotide sequence selected from SEQ ID NOs: 7, 9 or 13; and the second gRNA comprises a second target sequence comprising a nucleotide sequence of SEQ ID NO: 11.;

[00020] In some embodiments, the first gRNA comprises a first backbone sequence and the second gRNA comprises a second backbone sequence, wherein the first backbone sequence and the second backbone sequence comprise a nucleotide sequence. Petition 870250103694, dated 12 / 11 / 2025, pp. 106 / 211 9 / 97 selected from SEQ ID NO: 20 or 21.

[00021] In some embodiments, i) the first gRNA comprises a nucleotide sequence selected from SEQ ID NOs: 2, 6, 8, 16, or 18; and the second gRNA comprises a nucleotide sequence from SEQ ID NO: 4, or ii) the first gRNA comprises a nucleotide sequence selected from SEQ ID NOs: 10, 14, or 19; and the second gRNA comprises a nucleotide sequence from SEQ ID NO: 12.

[00022] In some embodiments, the first gRNA, the second gRNA, or both the first and second gRNAs, comprise one or more chemical modifications of a ribonucleotide, a ribonucleotide base, or a phosphodiester bond. In some embodiments, the one or more chemical modifications comprise at least one chemically modified phosphodiester bond. In some embodiments, the at least one chemically modified phosphodiester bond is a phosphorothioate bond. In some embodiments, the composition comprises at least two phosphorothioate bonds at the 5'-terminus of the first gRNA, the second gRNA, or both the first and second gRNAs. In some embodiments, the composition comprises a 2' O-Me chemical modification at the 3'-terminus of the first gRNA, the second gRNA, or both the first and second gRNAs.

[00023] In some embodiments, the dCas9 of the fusion protein and / or the second fusion protein is derived from a Cas9 polypeptide of S. pyogenes or a Cas9 polypeptide of S. aureus. In some embodiments, the C-terminal of dCas9 or its inactivated nuclease domain is joined to the N-terminal of the Clo051 polypeptide or its nuclease domain via a peptide linker sequence selected from GGGGS or SEQ ID NO: 23. In some embodiments, the first fusion protein comprises the amino acid sequence of SEQ ID NO: 39, 41, 42, or 43. In some embodiments, the second fusion protein comprises the Petition 870250103694, dated 12 / 11 / 2025, pp. 107 / 211 10 / 97 amino acid sequence of SEQ ID NO: 39, 41, 42, or 43. In some embodiments, the first fusion protein and the second fusion protein are identical. In some embodiments, the first fusion protein and the second fusion protein are different.

[00024] In some embodiments, the first polynucleotide encoding the first fusion protein, the second polynucleotide encoding the second fusion protein, or both the first polynucleotide and the second polynucleotide, are one mRNA. In some embodiments, the mRNA comprises a 5'-cap.

[00025] The disclosure provides a composition comprising: i) a first gRNA comprising a nucleotide sequence of SEQ ID NO: 2, a second gRNA comprising a nucleotide sequence of SEQ ID NO: 4, a first polynucleotide sequence encoding a first fusion protein of SEQ ID NO: 39 and a second polynucleotide sequence encoding a second fusion protein of SEQ ID NO: 39; ii) a first gRNA comprising a nucleotide sequence of SEQ ID NO: 6, a second gRNA comprising a nucleotide sequence of SEQ ID NO: 4, a first polynucleotide sequence encoding a first fusion protein of SEQ ID NO: 39 and a second polynucleotide sequence encoding a second fusion protein of SEQ ID NO: 39;iii) a first gRNA comprising a nucleotide sequence of SEQ ID NO: 8, a second gRNA comprising a nucleotide sequence of SEQ ID NO: 4, a first polynucleotide sequence encoding a first fusion protein of SEQ ID NO: 41, and a second polynucleotide sequence encoding a second fusion protein of SEQ ID NO: 41; iv) a first gRNA comprising a nucleotide sequence of SEQ ID NO: 10, a second gRNA comprising a nucleotide sequence; Petition 870250103694, dated 12 / 11 / 2025, pp. 108 / 211 11 / 97 of SEQ ID NO: 12, a first polynucleotide sequence encoding a first fusion protein of SEQ ID NO: 39 and a second polynucleotide sequence encoding a second fusion protein of SEQ ID NO: 42; v) a first gRNA comprising a nucleotide sequence of SEQ ID NO: 14, a second gRNA comprising a nucleotide sequence of SEQ ID NO: 12, a first polynucleotide sequence encoding a first fusion protein of SEQ ID NO: 42 and a second polynucleotide sequence encoding a second fusion protein of SEQ ID NO: 42; vi) a first gRNA comprising a nucleotide sequence of SEQ ID NO: 19, a second gRNA comprising a nucleotide sequence of SEQ ID NO: 12, a first polynucleotide sequence encoding a first fusion protein of SEQ ID NO: 42 and a second polynucleotide sequence encoding a second fusion protein of SEQ ID NO: 42;vii) a first gRNA comprising a nucleotide sequence of SEQ ID NO: 16, a second gRNA comprising a nucleotide sequence of SEQ ID NO: 4, a first polynucleotide sequence encoding a first fusion protein of SEQ ID NO: 41 and a second polynucleotide sequence encoding a second fusion protein of SEQ ID NO: 41; or viii) a first gRNA comprising a nucleotide sequence of SEQ ID NO: 18, a second gRNA comprising a nucleotide sequence of SEQ ID NO: 4, a first polynucleotide sequence encoding a first fusion protein of SEQ ID NO: 41 and a second polynucleotide sequence encoding a second fusion protein of SEQ ID NO: 41.

[00026] In some embodiments, the composition is encapsulated in at least one lipid nanoparticle (LNP) comprising: about 40.75 mol% of a compound of Formula (I), Petition 870250103694, dated 12 / 11 / 2025, pp. 109 / 211 12 / 97

[00027] Formula (I): approximately 51.75% cholesterol by moles, approximately 5% DOPC by moles and approximately 2.5% DMG-PEG2000 by moles; wherein the first polynucleotide and the second polynucleotide are RNA molecules, and wherein the ratio of lipid to RNA molecule in at least one nanoparticle is approximately 120:1 (w / w).

[00028] In some embodiments, the composition is encapsulated in at least one LNP comprising: about 54% SS-OP by mol, about 35% cholesterol by mol, about 5% DOPC by mol, about 5% DSPC by mol and about 1% DMG-PEG2000 by mol, wherein the first polynucleotide and the second polynucleotide are an RNA molecule, and wherein the ratio of lipid to RNA molecule in at least one nanoparticle is about 100:1 (w / w) and the total lipid is 25 nM.

[00029] In some embodiments, the compound is for use in modifying an HBG1 gene, an HBG2 gene, a BCL11A gene, or a combination thereof in a cell.

[00030] Disclosure provides a method for modifying a cell population comprising contacting the cell population with either of the disclosure compositions, wherein the first gRNA forms a complex with the first target sequence and the first fusion protein, and the second gRNA forms a complex with the second target sequence and the second fusion protein, thereby generating an indel between the first target sequence and the Petition 870250103694, dated 12 / 11 / 2025, pages 110 / 211 13 / 97 second target sequence and producing a modified cell population. In some embodiments, indel causes the inactivation of a BCL11A gene.

[00031] In some embodiments, the modified cell population exhibits an approximately 4- to approximately 9-fold increase in gamma globulin expression compared to an unmodified cell population. In some embodiments, the modified cell population exhibits an increased level of fetal hemoglobin (HbF) expression compared to an unmodified cell population.

[00032] In some embodiments, the cells are hematopoietic stem cells and precursor cells (HSPCs). In some embodiments, the HSPCs are capable of differentiating into erythroid progenitor cells.

[00033] Disclosure provides a modified cell population according to any of the disclosure methods.

[00034] The disclosure provides a method for treating a betahemoglobinopathy in an individual who needs it, comprising administering to an individual any of the compositions or cells of the disclosure. In some embodiments, the betahemoglobinopathy is betathalassemia or sickle cell anemia. Brief Description of the Figures

[00035] FIGURE 1 is a graph showing indels in HSPCs after editing with compositions comprising Cas-CLOVER and different concentrations of gRNA pairs targeting HBG1 or HBG2. On the y-axis, indels are shown as a percentage of modified reads relative to the total sequencing reads. The x-axis shows the gRNA pairs tested (Pair #1, Pair #2, Pair #3, and Pair #4). Each gRNA pair was tested at three increasing concentrations: 40, 200, and 400 pg / ml.

[00036] FIGURE 2 is a graph showing indels in HSPCs after editing with compositions comprising Cas-CLOVER and a high Petition 870250103694, dated 12 / 11 / 2025, pp. 111 / 211 14 / 97 concentration (400 pg / ml) or a low concentration (200 pg / ml) of gRNA pairs that target HBG1 or HBG2.

[00037] FIGURE 3 is a graph showing indels in HSPCs after editing with compositions comprising Cas-CLOVER and different concentrations of gRNA pairs targeting HBG1 or HBG2. On the y-axis, indels are shown as a percentage of modified reads relative to the total sequencing reads. The x-axis shows the gRNA pairs tested (Pair #2, Pair #3, and Pair #4).

[00038] FIGURE 4A shows a graph illustrating the absolute number of colony-forming unit (CFU) types for HSPCs after editing with compositions comprising Cas-CLOVER and different gRNA pairs targeting HBG1 or HBG2. Three controls were tested: EP only (nucleofection / electroporation only), CC only (Cas-CLOVER mRNA only), and sgRNA only. The following cell types were analyzed: CFU-GEMM (CFU-Granulocyte / Erythrocyte / Macrophage / Megakaryocyte), CFU-GM (CFU-Granulocyte / Macrophage), BFU-E (Erythroid Burst Forming Unit); and CFU-E (CFU-Erythroid).

[00039] FIGURE 4B shows a graph showing the absolute number of colony-forming unit (CFU) types for HSPCs after editing with compositions comprising Cas-CLOVER and different gRNA pairs targeting HBG1 or HBG2. Three controls were tested: EP only (nucleofection / electroporation only), CC only (Cas-CLOVER mRNA only), and sgRNA only. The following cell types were analyzed: CFU-GEMM (CFU-Granulocyte / Erythrocyte / Macrophage / Megakaryocyte), CFU-GM (CFU-Granulocyte / Macrophage), BFU-E (Erythroid Burst Forming Unit); and CFU-E (CFU-Erythroid).

[00040] FIGURE 5 is a graph showing the expression of HBG mRNA in HSPCs after editing with compositions comprising CasPetition 870250103694, dated 12 / 11 / 2025, page 112 / 211 15 / 97 CLOVER and different gRNA pairs that target HBG1 or HBG2. RT-qPCR results were normalized for HBB on days 14, 18, and 21 during erythroid differentiation. Adult blood and umbilical cord blood samples were used as negative and positive controls, respectively.

[00041] FIGURE 6 is a graph showing the HbF protein expression levels in HSPCs after editing with compositions comprising Cas-CLOVER and different gRNA pairs targeting HBG1 or HBG2. The left y-axis shows the percentage of F cells determined by flow cytometry. The right y-axis shows the mean fluorescence intensity of the HbF signal per F cell relative to the EP-only control (nucleofection / electroporation only).

[00042] FIGURE 7 is a schematic diagram of the disclosure composition. A first fusion protein (e.g., Cas-Clover comprising a dCas9-Clo051 ligand) is complexed with a first gRNA at the 5' end of the genomic region. A second fusion protein (e.g., Cas-Clover comprising a dCas9-Clo051 ligand) is complexed with a second gRNA at the 3' end of the genomic region. Targeting using gRNAs provides highly efficient and precise targeting. Only when the Clo051 nucleases of the first fusion protein and the second fusion protein are brought close together is a cut made in the genomic DNA template. In some cases, the cut is made in an HBG1 gene, an HBG2 gene, a BCL11A gene, or a combination thereof.

[00043] FIGURE 8 is a graph showing indels in HSPCs after editing with compositions comprising Cas-CLOVER variants and gRNA pairs that target HBG1 or HBG2.

[00044] All documents cited in this document, including any patents or applications with cross-references or related references, are incorporated into this document by reference in their Petition 870250103694, dated 12 / 11 / 2025, pp. 113 / 211 16 / 97 entirety for all purposes, unless expressly excluded or otherwise limited. Citation of any document does not constitute admission that it is prior art with respect to any invention disclosed or claimed herein, or that, alone or in combination with any other reference or references, it teaches, suggests or discloses such invention. Furthermore, to the extent that any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition ascribed to that term in this document shall prevail. Detailed Description

[00045] This disclosure provides compositions and methods for genetically modifying a genome to include a polynucleotide insertion, deletion, and / or substitution in chromosomal DNA that enhances the transcription of the HBG1 and / or HBG2 genes, which encode the γA and YG subunits of hemoglobin, respectively. In particular, this disclosure overcomes problems associated with current technologies by providing a method for efficiently genetically modifying cellular genomes to include polynucleotide insertions, deletions, and / or substitutions, which is advantageous in the therapeutic expression of fetal hemoglobin (HbF) for the treatment of hemoglobinopathies.

[00046] Fetal hemoglobin (HbF) expression can be induced using various genomic strategies. For example, HbF expression can be induced by targeted disruption of the proximal region to the target sequence of the HBG1 and HBG2 promoters, and / or by erythroid cell-specific expression of a transcriptional repressor, BCL11A (also discussed in International Patent Publication No. WO 2015 / 148860 by Friedland et al. (“Friedland”), published on October 1, 2015, which is incorporated by reference in its entirety herein), which encodes a repressor Petition 870250103694, dated 12 / 11 / 2025, pp. 114 / 211 17 / 97 which silences HBG1 and HBG2 (Canvers 2015). Genome-wide genetic mapping and association studies have discovered genetic loci in B-cell lymphoma / leukemia 11A (BCL11A), an Xnm1 variant upstream of the gamma 1 subunit of hemoglobin (HBG1). Supporting studies have reported that hemoglobin switching is controlled by the activity of epigenetic modulators such as BCL11A. The HBG promoter region for the HBG1 and HBG2 genes comprises a DNA-binding region for BCL11A, which is a potent silencer of HbF expression. BCL11A binding to the HBG1 promoter inhibits the expression of gamma 1 and 2 subunits, potentially leading to inhibition of the γ-globin to β-globin switching process.

[00047] The genome editing systems in this disclosure may include two or more fusion proteins (e.g., Cas-Clover) and two or more gRNAs with a target domain complementary to a sequence in or near the target region. In certain embodiments, the DNA-binding region of BCL11A is targeted for disruption. In certain embodiments, the promoter region of HBG1 and / or HBG2 is targeted for disruption. In certain embodiments, the genome editing systems disclosed herein may be used to introduce a polynucleotide insertion, deletion, and / or substitution in the target region.

[00048] The treatment of hemoglobinopathies by gene therapy and / or genome editing is complicated by the fact that the cells phenotypically affected by the disease, erythrocytes or RBCs, are enucleated and do not contain genetic material encoding the aberrant hemoglobin (Hb) protein subunits or the γA or γG subunits targeted by the exemplary genome editing approaches described above. This complication is addressed, in certain embodiments of this disclosure, by altering cells that are competent to differentiate into or otherwise give rise to erythrocytes. The cells in the erythroid lineage that are altered according to various embodiments of this disclosure include, without limitation, stem cells and Petition 870250103694, dated 12 / 11 / 2025, pages 115 / 211 18 / 97 hematopoietic progenitor cells (HSPCs), erythroblasts (including basophilic, polychromatic and / or orthochromatic erythroblasts), proerythroblasts, polychromatic erythrocytes or reticulocytes, embryonic stem cells (ES) and / or induced pluripotent stem cells (iPSCs). These cells can be altered in situ (e.g., within an individual's tissue) or ex vivo.

[00049] This disclosure overcomes problems associated with current technologies by providing compositions comprising genetically engineered fusion molecules (e.g., Cas-Clover) for targeted reduction or elimination of gene products in a cell for use in in vivo gene therapy. The genetically engineered fusion molecule compositions of the disclosure are useful for the treatment of genetic diseases. Non-limiting examples of genetic diseases include hemoglobinopathies such as sickle cell anemia or beta thalassemia. Consequently, methods for the production of genetically engineered fusion molecules and pharmaceutical formulations thereof (e.g., lipid nanoparticle formulations) for use in in vivo delivery are also provided.As a non-limiting example, the magnitude of the improvement provided by the disclosed compositions could cross a fundamental therapeutic threshold to fully enable the activation of fetal hemoglobin (HbF) expression, which would provide therapeutic efficacy for the functional correction of sickle cell anemia or beta thalassemia. Methods for Targeted Locus Genome Editing: Genetic Compositions and Editing Methods

[00050] This disclosure provides a gene-editing composition as well as a cell comprising the gene-editing composition. The gene-editing composition may comprise a sequence encoding a DNA localization domain and a sequence encoding a nuclease protein or a nuclease domain thereof. The sequence that Petition 870250103694, dated 12 / 11 / 2025, pp. 116 / 211 19 / 97 encodes a nuclease protein, or the sequence encoding a nuclease domain thereof may comprise a DNA sequence, an RNA sequence, or a combination thereof. The DNA localization domain may comprise one or more CRISPR / Cas proteins, a Transcription Activator-Like Effector Nuclease (TALEN), a Zinc Finger Nuclease (ZFN), and an endonuclease. The dCas9-Clo051 (Cas-CLOVER) fusion proteins are examples.

[00051] The nuclease protein or nuclease domain thereof may comprise a nuclease-inactivated Cas protein (dCas) and an endonuclease. The endonuclease may comprise a Clo051 nuclease or a nuclease domain thereof. The gene-editing composition may comprise a fusion protein. The fusion protein may comprise a nuclease-inactivated Cas9 protein (dCas9) and a Clo051 nuclease or a Clo051 nuclease domain. The gene-editing composition may further comprise a guide sequence. In some embodiments, the guide sequence comprises an RNA sequence.

[00052] The disclosure provides compositions comprising a Cas9 operatively linked to an effector. The disclosure provides a fusion protein comprising, essentially consisting of, or consisting of a DNA localization component and an effector molecule, wherein the effector comprises a Cas9. A Cas9 construct from the disclosure may comprise an effector comprising a type IIS endonuclease. A Staphylococcus aureus Cas9 with an active catalytic site comprises the amino acid sequence SEQ ID NO: 30.

[00053] The disclosure provides compositions comprising an inactivated Cas9 (dSaCas9) operatively linked to an effector. The disclosure provides a fusion protein comprising, essentially consisting of, or consisting of a DNA localization component and an effector molecule, in Petition 870250103694, dated 12 / 11 / 2025, pp. 117 / 211 20 / 97 that the effector comprises an inactivated Cas9 (dSaCas9). An inactivated Cas9 (dSaCas9) disclosure construct may comprise an effector comprising a type IIS endonuclease. A dSaCas9 comprises the amino acid sequence of SEQ ID NO: 31, which includes a D10A mutation and an N580A mutation to inactivate the catalytic site.

[00054] Disclosure provides compositions comprising an inactivated Cas9 (dCas9) operatively linked to an effector. Disclosure provides a fusion protein comprising, essentially consisting of, or consisting of a DNA localization component and an effector molecule, wherein the effector comprises an inactivated Cas9 (dCas9). An inactivated Cas9 (dCas9) construct from disclosure may comprise an effector comprising a type IIS endonuclease.

[00055] dCas9 can be isolated from or derived from Streptococcus pyogenes. dCas9 may comprise a dCas9 with substitutions at amino acid positions 10 and 840, which inactivate the catalytic site. In some respects, these substitutions are D10A and H840A. dCas9 may comprise the amino acid sequence SEQ ID NO: 32 or SEQ ID NO: 33.

[00056] An exemplary Clo051 nuclease domain comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 34. In some respects, the Clo051 nuclease domain comprises at least one amino acid substitution. In some respects, the amino acid substitution is in the alpha-helix-loop domain of the Clo051 nuclease. In some respects, the amino acid substitution is at position 35, 37, 60, 92, 98, 100, or 146 of SEQ ID NO: 34. In some respects, the amino acid substitution is at position 37 of SEQ ID NO: 34. In some respects, the amino acid substitution is at positions 37 and 92 of SEQ ID NO: 34.

[00057] A dCas9-Clo051 (Cas-CLOVER) fusion protein Petition 870250103694, dated 12 / 11 / 2025, pp. 118 / 211 21 / 97 exemplary may comprise, consist essentially of, or consist of the amino acid sequence of SEQ ID NO: 35. The exemplary dCas9-Clo051 fusion protein may be encoded by a polynucleotide comprising, consists essentially of, or consists of the nucleic acid sequence of SEQ ID NO: 36. The nucleic acid encoding the dCas9-Clo051 fusion protein may be DNA or RNA.

[00058] An exemplary dCas9-Clo051 (Cas-CLOVER) fusion protein may comprise, consist essentially of, or consist of the amino acid sequence of SEQ ID NO: 37. The exemplary dCas9Clo051 fusion protein may be encoded by a polynucleotide comprising, consists essentially of, or consists of the nucleic acid sequence of SEQ ID NO: 38. The nucleic acid encoding the dCas9-Clo051 fusion protein may be DNA or RNA.

[00059] An exemplary disclosure dCas9-Clo051 fusion protein (CasCLOVER) may additionally comprise at least one nuclear localization sequence (NLS). In some embodiments, the disclosure dCas9-Clo051 fusion protein comprises at least two nuclear localization sequences. In some embodiments, the NLS is at the N'-terminal end of the dCas9-Clo051 fusion protein (NLS-dCas9-Clo051). In some embodiments, the NLS is at the C-terminal end of the dCas9-Clo051 fusion protein (dCas9-Clo051-NLS). In some embodiments, the NLS is at both the N'-terminal and C'-terminal ends of the dCas9-Clo051 fusion protein (NLS-dCas9-Clo051-NLS or wild-type Cas-CLOVER or dspCas9 Ca-CLOVER).

[00060] The NLS-dCas9-Clo051-NLS fusion protein (“wild-type CasCLOVER” or “dspCas9 Cas-CLOVER”) may comprise, consist essentially of, or consist of the amino acid sequence of SEQ ID NO: 39. Petition 870250103694, dated 12 / 11 / 2025, pp. 119 / 211 22 / 97

[00061] Amino acid sequence of dspCas9 Cas-CLOVER (the amino acid sequence of NLS is in bold and underlined; the ligand is in bold and italicized): MAPKKKKRKVEGIKSNISLLKDELRGQISHISHEYLSLIDLAFDSKQ NRLFEMKVLELVNEYGFKGRHLGGSRKPDGIVYSSTLEDNFGIIVDTKAYSEG YSLPISQADEMERYVRENSNRDEEVNPNKWWENFSEEVKKYYFVFISGSFKG KFEEQLRRLSMTTGVNGSAVNVVNLLLGAEKIRSGEMTIEELERAMFNNSEFIL KY GGGGS DKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKKNLI GALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRL EESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAI LSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQ LSKDTYDDDLNLLAQIGDQYADLFLAAKNLSDAILSDILRVNTEITKAPLSAS MIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFY KFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQED FYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVV DKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMR KPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNA SLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDD KVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIH DDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQL QNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKVLTR SDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSEL DKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDF RKDFQFYKVREINNYHHAHDAYLNAVGTALIKKYPKLESEFVYGDYKVYDVR KMIAKSEQEIGKATAKYFFYSNIMNFKTEITLANGEIRKRPLIETNGETGEIVW DKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWD Petition 870250103694, de 12 / 11 / 2025, pág. 120 / 211 23 / 97 PKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKLSVKELLGITIMERSSFEKNPIDF LEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNF LYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKV LSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDA TLIHQSITGLYETRIDLSQLGGDGSPKKKRKVSS (SEQ ID NO: 39).

[00062] The nucleic acid encoding the NLSdCas9-Clo051-NLS fusion protein (“wild-type Cas-CLOVER” or “dspCas9 CasCLOVER”) can be DNA or RNA. In some embodiments, a dCas9-Clo051 fusion protein comprising two NLS regions is encoded by an mRNA sequence comprising, consisting essentially of, or consisting of SEQ ID NO: 40.

[00063] The NLS-dCas9-Clo051-NLS fusion protein (“dspCas9XL Cas-CLOVER” or “dspCas9 5xGGGGS Cas-CLOVER”) may comprise, consist essentially of, or consist of the amino acid sequence of SEQ ID NO: 41.

[00064] The amino acid sequence “dspCas9-XL Cas-CLOVER” (the NLS amino acid sequence is in bold and underlined; the linker is in bold and italics): MAPKKKRKVEGIKSNISLLKDELRGQISHISHEYLSLIDLAFDSKQ NRLFEMKVLELLVNEYGFKGRHLGGSRKPDGIVYSTTLEDFGIIVDTKAYSEG YSLPISQADEMERYVRENSNRDEEVNPNKWWENFSEEVKKYYFVFISGSFKG KFEEQLRRLSMTTGVNGSAVNVVNLLLGAEKIRSGEMTIEELERAMFNNSEFIL KY GGGGSGGGSGGGSGGGSGGGSGGGS DKKYSIGLAIGTNSVGWAVITDE YKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKN RICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEK YPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFI QLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGN LIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAK Petition 870250103694, de 12 / 11 / 2025, pág. 121 / 211 24 / 97 NLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEI FFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRT FDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGN SRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKH SLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLK EDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVL TLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQ SGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLA GSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERM KRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSD YDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLL NAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNT KYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGT ALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEI TLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTG GFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKK LKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKR MLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAP AAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDGSPKKKR KVSS (SEQ ID NO: 41).

[00065] The NLS-dCas9-Clo051-NLS fusion protein (“dsaCas9 Cas-CLOVER”) may comprise, consist essentially of, or consist of the amino acid sequence of SEQ ID NO: 42.

[00066] The amino acid sequence “dsaCas9 Cas-CLOVER” (the NLS amino acid sequence is in bold and underlined; the linker is in bold and italics): MAPKKKRKVEGIKSNISLLKDELRGQISHISHEYLSLIDLAFDSKQ Petition 870250103694, dated 12 / 11 / 2025, pp. 122 / 211 25 / 97 NRLFEMKVLELLVNEYGFKGRHLGGSRKPDGIVYSTTLENFGIIVDTKAYSEG YSLPISQADEMERYVRENSNRDEEVNPNKWWENFSEEVKKYYFVFISGSFKG KFEEQLRRLSMTTGVNGSAVNVVNLLGAEKIRSGEMTIEELERAMFNNSEFIL KY GGGGS KRNYILGLAIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRR SKRGARRLKRRRRHRIQRVKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLS EEEFSAALLHLAKRRGVHNVNEVEEDTGNELSTEQISRNSKALEEKYVAELQ LERLKKDGEVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQSFIDTYIDLLETR RTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYAYNADLYNAL NDLNNLVITRDENEKLEYEKFQIIENVFKQKKKPTLKQIAKEILVNEEDIKGYRV TSTGKPEFTNLKVYHDIKDITARKEIIENAELLDQIAKILTIYQSSEDIQEELTNLN SELTQEEIEQISNLKGYTGTHNLSLKAINLILDELWHTNDNQIAIFNRLKLVPKKV DLSQQKEIPTTLVDDFILSPVVKRSFIQSIKVINAIIKKYGLPNDIIIELAREKNSKD AQKMINEMQKRNRQTNERIEEIIRTTGKENAKYLIEKIKLHDMQEGKCLYSLEAI PLEDLLNNPFNYEVDHIIPRSVSFDNSFNNKVLKQQEEASKKGNRTPFQYLSS SDSKISYETFKKHILNLAKGKGRISKTKKKEYLLEERDINRFSVQKDFINRNLVDT RYATRGLMNLLRSYFRVNNLDVKVKSINGGFTSFLRRKWKFKKERNKGYKHH AEDALIIANADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEIETQEYKEIFIT PHQIKHIKDFKDYKYSHRVDKKPNRELINDTLYSTRKDDKGNTLIVNNLNGLYDKDNDKLKKLINKSPEKLLMYHHDPQTYQKLKLIMEQYGDEKNPLYKYYEETGN YLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSRNKVVKLSLKPYRFDVY LDNGVYKFVTVKNLDVIKKENYYEVNSKCYEEAKKLKKISNQAEFIASFYNNDLI KINGELYRVIGVNNDLLNRIEVNMIDITYREYLENMNDKRPPRIIKTIASKTQSIKK YSTDILGNLYEVKSKKHPQIIKKGGSPKKKRKVSS (SEQ ID NO: 42).

[00067] The NLS-dCas9-Clo051-NLS fusion protein (“dsaCas9XL Cas-CLOVER” from dsaCas9 5xGGGGS Cas-CLOVER”) may comprise, consist essentially of, or consist of the amino acid sequence of SEQ ID NO: 43.

[00068] The amino acid sequence “dsaCas9-XL Cas-CLOVER” Petition 870250103694, dated 12 / 11 / 2025, pp. 123 / 211 26 / 97 (the NLS amino acid sequence is in bold and underlined; the ligand is in bold and italics): MAPKKKRKVEGIKSNISLLKDELRGQISHISHEYLSLIDLAFDSKQ NRLFEMKVLELLVNEYGFKGRHLGGSRKPDGIVYSTTLEDFGIIVDTKAYSEG YSLPISQADEMERYVRENSNRDEEVNPNKWWENFSEEVKKYYFVFISGSFKG KFEEQLRRLSMTTGVNGSAVNVNLLLGAEKIRSGEMTIEELERAMFNNSEFIL KYGGGSGGGSGGGSGGGSGGGSGGGSKRNYILGLAIGITSVGYGIIDYETR DVIDAGVRLFKEANVENNEGRRSKRGARRLKRRRRHRIQRVKKLLFDYNLLTD HSELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHNVNEVEEDTGNEL STKEQISRNSKALEEKYVAELQLERLKKDGEVRGSINRFKTSDYVKEAKQLLKV QKAYHQLDQSFIDTYIDLLETRRTYEGPGEGSPFGWKDIKEWYEMLMGHCT YFPEELRSVKYAYNADLYNALNDLNNLVITRDENEKLEYYEKFQIIENVFKQKK KPTLKQIAKEILVNEEDIKGYRVTSTGKPEFTNLKVYHDIKDITARKEIIENAELLD QIAKILTIYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSLKAINLILDEL WHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLVDDFILSPVVKRSFIQSIKVINAI IKKYGLPNDIIIELAREKNSKDAQKMINEMQKRNRQTNERIEEIIRTTGKENAKYL IEKIKLHDMQEGKCLYSLEAIPLEDLLNNPFNYEVDHIIPRSVSFNDNSFNNKVLV KQEEASKKGNRTPFQYLSSSDSKISYETFKKHILNLAKGKGRISKTKKEYLLEE RDINRFSVQKDFINRNLVDTRYATRGLMNLRSYFRVNNLDVKVKSINGGFTS FLRRKWKFKKERNKGYKHHAEDALIIANADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEIETEQEYKEIFITPHQIKHIKDFKDYKYSHRVDKKPNRELINDTLYS TRKDDKGNTLIVNNLNGLYDKDNDKLKKLINKSPEKLLMYHHDPQTYQKLKLIM EQYGDEKNPLYKYYEETGNYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYP NSRNKVVKLSLKPYRFDVYLDNGVYKFVTVKNLDVIKKENYYEVNSKCYEEAK KLKKISNQAEFIASFYNNDLIKINGELYRVIGVNNDLLNRIEVNMIDITYREYLEN MNDKRPPRIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQIIKKGGSPKKKRKV SS (SEQ ID NO: 43).

[00069] A cell comprising the editing composition Petition 870250103694, dated 12 / 11 / 2025, pp. 124 / 211 27 / 97 genetics can express the gene-editing composition in a stable or transient way. GRNAS

[00070] In this document, the term “guide sequence” or “spacer” in the context of a Cas-Clover system or a CRISPRCas9 system, comprises any polynucleotide molecule having sufficient complementarity with a target nucleic acid sequence to hybridize with the target nucleic acid sequence and direct sequence-specific binding of a complex targeting the nucleic acid to the target nucleic acid sequence. The guide sequence may comprise RNA and DNA polynucleotides. The guide sequence may form a duplex with a target sequence. The duplex may be a DNA duplex, an RNA duplex, or an RNA / DNA duplex.The terms guide molecule, guide RNA, gRNA, single guide RNA, and sgRNA are used interchangeably in this document to refer to RNA-based molecules that are capable of forming a complex with a Cas-Clover or CRISPR-Cas protein and that comprise a guide sequence with sufficient complementarity to a target nucleic acid sequence to hybridize with the target nucleic acid sequence and direct sequence-specific binding of the complex to the target nucleic acid sequence. The guide molecule or guide RNA may encompass RNA-based molecules with one or more chemical modifications (e.g., by chemical linking of two ribonucleotides or by substitution of one or more ribonucleotides for one or more deoxyribonucleotides), as described in this document.The guide sequence may also partially comprise RNA- and DNA-based nucleotides in which the molecule is chimeric to RNA and DNA nucleobases (e.g., containing ribose or deoxyribose sugars).

[00071] The term target region, target sequence or protospacer, as used interchangeably in this document, Petition 870250103694, dated 12 / 11 / 2025, pp. 125 / 211 28 / 97 refers to the target gene region or target genomic site that the Cas-Clover system or the CRISPR / Cas9-based system targets. The Cas-Clover system or the CRISPR / Cas9-based system may include at least one gRNA, where the gRNAs target different DNA sequences. Target DNA sequences may overlap. The CasClover system may include at least two gRNAs, where the gRNAs target different DNA sequences. The target sequence or protospacer may be followed by a PAM sequence at the 3' end of the protospacer. Different CRISPR Type II systems have different PAM requirements. For example, the S. pyogenes Type II system uses an NGG sequence, where N can be any nucleotide.

[00072] The guide RNA or guide RNA of a Cas-Clover protein or a CRISPR-Cas protein may comprise a tracr-mate sequence (comprising a direct repeat in the context of an endogenous CRISPR system) and a guide sequence (also referred to as a spacer in the context of an endogenous CRISPR system). In some embodiments, the Cas-Clover or CRISPR-Cas system or complex, as described herein, does not comprise and / or does not depend on the presence of a tracr sequence. In certain embodiments, the guide molecule may comprise, consist essentially of, or consist of a direct repeat sequence fused or linked to a guide sequence or spacer sequence.

[00073] In some embodiments, the guide RNA comprises a guide sequence and a support sequence. In some embodiments, the support sequence is isolated from Streptococcus pyogenes. In some embodiments, the support sequence from Streptococcus pyogenes comprises the nucleic acid sequence: GUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAA CUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 19). In Petition 870250103694, dated 12 / 11 / 2025, pp. 126 / 211 29 / 97 In some embodiments, the support sequence is isolated from Staphylococcus aureus. In some embodiments, the Staphylococcus aureus support sequence comprises the nucleic acid sequence: GUUUUAGUACUCUGGAAACAGAAUCUACUAAAACAAGGCAA AAUGCCGUGUUUAUCUCGUCAACUUGUUGGCGAGAUUUU (SEQ ID NO: 20).

[00074] In certain embodiments, the guide sequence or spacer length of the guide molecules is 15 to 50 nucleotides in length. In certain embodiments, the guide RNA spacer length is at least 15 nucleotides in length. In certain embodiments, the spacer length is from 15 to 17 nucleotides in length, from 17 to 20 nucleotides in length, from 20 to 24 nucleotides in length, from 23 to 25 nucleotides in length, from 24 to 27 nucleotides in length, from 27 to 30 nucleotides in length, from 30 to 35 nucleotides in length, or greater than 35 nucleotides in length.

[00075] In some realizations, the guide sequence is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149 or 150 nucleotides in length.

[00076] In some embodiments, the sequence of the guide molecule (direct repeat and / or spacer) is selected to reduce the degree of secondary structure within the guide molecule. In some embodiments, approximately 75%, 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 1% or less of the nucleotides of Petition 870250103694, dated 12 / 11 / 2025, pp. 127 / 211 30 / 97 Guide RNA that targets nucleic acids participates in self-complementary base pairing when optimally folded. Optimal folding can be determined by any suitable polynucleotide folding algorithm. Some programs rely on the calculation of the minimum Gibbs free energy. An example of one such algorithm is mFold, as described by Zuker and Stiegler (Nucleic Acids Res. 9 (1981), 133-148). Another example of a folding algorithm is the RNAfold online web server, developed at the Institute for Theoretical Chemistry at the University of Vienna, using the centroid structure prediction algorithm (see, for example, AR Gruber et al., 2008, Cell 106(1): 23-24; and PA Carr and GM Church, 2009, Nature Biotechnology 27(12): 1151-62).

[00077] As described above, the Cas-Clover system and the CRISPR / Cas9 system utilize one or more target gRNAs that provide the target for the Cas-Clover system and the CRISPR / Cas9-based system. The gRNA can be a fusion of two non-coding RNAs: a crRNA and a tracrRNA. The sgRNA can target any desired DNA sequence by changing the sequence encoding a 20 bp protospacer that confers target specificity through complementary base pairing with the desired target DNA. The gRNA mimics the naturally occurring crRNA:tracrRNA duplex involved in the Type II Effector system. This duplex, which may include, for example, a 42-nucleotide crRNA and a 75-nucleotide tracrRNA, acts as a guide for Cas9 to cleave the target nucleic acid.

[00078] In some embodiments, the gRNA targets a BCL11A binding site in an HBG promoter region upstream of the target gene (e.g., HBG1 or HBG2 gene locus), for example, between 0 and 1000 bp upstream of a target gene. In some embodiments, the gRNA targets near a BCL11A binding site in an HBG promoter region upstream of the HBG1 gene locus or HBG2 gene locus. In Petition 870250103694, dated 12 / 11 / 2025, pp. 128 / 211 31 / 97 some realizations, the gRNA targets a region between 0 and 50 bp, 0 and 100 bp, 0 and 150 bp, 0 and 200 bp or 0 and 250 bp upstream or downstream of the BCL11A binding site. In some embodiments, the gRNA targets a region between 0-50 bp, 0-100 bp, 0-150 bp, 0-200 bp, 0-250 bp, 0-300 bp, 0-350 bp, 0-400 bp, 0-450 bp, 0-500 bp, 0-550 bp, 0-600 bp, 0-650 bp, 0-700 bp, 0-750 bp, 0-800 bp, 0-850 bp, 0-900 bp, 0-950 bp, or 0-1000 bp upstream of the transcription start site of the target gene. In some embodiments, the gRNA targets a region within approximately 100 bp, approximately 200 bp, approximately 300 bp, approximately 400 bp, approximately 500 bp, approximately 600 bp, approximately 700 bp, approximately 800 bp, approximately 900 bp, approximately 1000 bp, approximately 1100 bp, approximately 1200 bp, approximately 1300 bp, approximately 1400 bp, or approximately 1500 bp upstream of the target gene.

[00079] A gRNA can be divided into a target-binding region and a Cas9-binding region. The target-binding region hybridizes with a target region in a target gene or intergenic region. Methods for designing such target-binding regions are known in the art; see, for example, Doench et al., Nat Biotechnol. (2014) 32: 1262-7; and Doench et al., Nat Biotechnol. (2016) 34: 184-91, incorporated herein by reference in their entirety. Design tools are available in, for example, Feng Zhang lab's target Finder, Michael Boutros lab's Target Finder (E-CRISP), RGEN Tools (Cas-OF Finder), CasFinder, and CRISPR Optimal Target Finder. In certain embodiments, the target-binding region may be between about 15 and about 50 nucleotides in length (approximately 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or approximately 50 nucleotides in length).In certain embodiments, the target-binding region may be between about 19 and about 21 nucleotides in length. In one embodiment, the target-binding region is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length. Petition 870250103694, dated 12 / 11 / 2025, pp. 129 / 211 32 / 97

[00080] In one embodiment, the target-binding region is complementary, for example, completely complementary, to the target region in the target gene. In one embodiment, the target-binding region is substantially complementary to the target region in the target gene. In one embodiment, the target-binding region comprises at most 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides that are not complementary to the target region in the target gene.

[00081] Exemplary gRNAs for disclosure include, but are not limited to, sequences to target the HBG1 gene locus, the HBG2 gene locus, or the BCL11A binding site in an HBG promoter region of the HBG1 or HBG2 gene loci.

[00082] In some embodiments, the first gRNA (also called left gRNA) binds to a template sequence at the 5' end of the target gene locus, and the second gRNA (also called right gRNA) binds to a template sequence at the 3' end of the target gene locus. A schematic diagram is shown in FIGURE 7.

[00083] The gRNAs used as examples of disclosure comprise, consist essentially of, or consist of the target sequences and full-length sequences, as shown in Table 1. Table 1. gRNAs exemplifying disclosure. Example gRNA Target gRNA sequence / total length Support Sequence SEQ ID NO: HBG 1 / 2 - gRNA first / left (Pair #1) Target sequence - GCUAUUGGUCA AGGCAAGGC SEQ ID NO: 1 HBG 1 / 2 first / left gRNA (Pair #1) S. pyogenes gRNA sequence GCUAUUGGUCA AGGCAAGGCGU UUUAGAGCUAG AAAUAGCAAGU UAAAAUAAGGC UAGUCCGUUAU CAACUUGAAAA AGUGGCACCGA GUCGGUGCUUU U SEQ ID NO: 2 Petition 870250103694, dated 12 / 11 / 2025, pp. 130 / 211 33 / 97 gRNA exemplary Target gRNA sequence / total length Support Sequence SEQ ID NO: HBG 1 / 2 - second / right gRNA (Pair #1, 2, 3, 7, 8) Target sequence - UAGUCUUAGAG UAUCCAGUG SEQ ID NO: 3 HBG 1 / 2 - second / right gRNA (Pair #1, 2, 3, 7, 8) S. pyogenes gRNA sequence UAGUCUUAGAG UAUCCAGUGGU UUUAGAGCUAG AAAUAGCAAGU UAAAAUAAGGC UAGUCCGUUAU CAACUUGAAAA AGUGGCACCGA GUCGGUGCUUU U SEQ ID NO: 4 HBG 1 / 2 first / left gRNA (Pair #2) Target sequence - CAAGGCUAUUG GUCAAGGCA SEQ ID NO: 5 HBG 1 / 2 first / left gRNA (Pair #2) S. gRNA sequence pyogenes CAAGGCUAUUG GUCAAGGCAGU UUUAGAGCUAG AAAUAGCAAGU UAAAAUAAGGC UAGUCCGUUAU CAACUUGAAAA AGUGGCACCGA GUCGGUGCUUU U SEQ ID NO: 6 HBG 1 / 2 first / left gRNA (Pair #3, 6) Target sequence - AAGGCUGGCCA ACCCAUGGG SEQ ID NO: 7 HBG 1 / 2 first / left gRNA (Pair #3) gRNA sequence S.pyogenes AAGGCUGGCCA ACCCAUGGGGU UUUAGAGCUAG AAAUAGCAAGU UAAAAUAAGGC UAGUCCGUUAU CAACUUGAAAA AGUGGCACCGA GUCGGUGCUUU U SEQ ID NO: 8 HBG 1 / 2 first / left gRNA (Pair #4) Target sequence - GGCAAGGCUGG CCAACCCAU SEQ ID NO: 9 HBG 1 / 2 first / left gRNA (Pair #4) S. pyogenes gRNA sequence GGCAAGGCUGG CCAACCCAUGU UUUAGAGCUAG AAAUAGCAAGU UAAAAUAAGGC UAGUCCGUUAU CAACUUGAAAA SEQ ID NO: 10. Petition 870250103694, dated 12 / 11 / 2025, pp. 131 / 211 34 / 97 Example gRNA Target gRNA sequence / total length Support Sequence SEQ ID NO: AGUGGCACCGA GUCGGUGCUUU U HBG 1 / 2 - gRNA second / right (Pair #4, 5, 6) Target sequence - GCAAACUUGAC CAAUAGUCU SEQ ID NO: 11 HBG 1 / 2 - gRNA second / right (Pair #4, 5, 6) S. aureus gRNA sequence GCAAACUUGAC CAAUAGUCUGU UUUAGUACUCU GGAAACAGAAU CUACUAAAACA AGGCAAAAUGC CGUGUUUAUCU CGUCAACUUGU UGGCGAGAUUU U SEQ ID NO: 12 HBG 1 / 2 - gRNA first / left - (Pair #5) Target sequence - AAGGCAAGGCU GGCCAACCC SEQ ID NO: 13 HBG 1 / 2 - gRNA first / left - (Pair #5) S. aureus gRNA sequence AAGGCAAGGCU GGCCAACCCGU UUUAGUACUCU GGAAACAGAAU CUACUAAAACA AGGCAAAAUGC CGUGUUUAUCU CGUCAACUUGU UGGCGAGAUUU U SEQ ID NO: 14 HBG 1 / 2 first / left gRNA (Pair #7) Target sequence - CCCAUGGGUGG AGUUUAGCC SEQ ID NO: 15 HBG 1 / 2 first / left gRNA (Pair #7) S. gRNA sequencepyogenes CCCAUGGGUGG AGUUUAGCCGU UUUAGAGCUAG AAAUAGCAAGU UAAAAUAAGGC UAGUCCGUUAU CAACUUGAAAA AGUGGCACCGA GUCGGUGCUUU U SEQ ID NO: 16 HBG 1 / 2 first / left gRNA (Pair #8) Target sequence - CCAUGGGUGGA GUUUAGCCA SEQ ID NO: 17 HBG 1 / 2 first / left gRNA - S. pyogenes gRNA sequence CCAUGGGUGGA GUUUAGCCAGU UUUAGAGCUAG SEQ ID NO: 18. Petition 870250103694, dated 12 / 11 / 2025, pp. 132 / 211 35 / 97 Example gRNA Target gRNA sequence / total length Support Sequence SEQ ID NO: (Pair #8) AAAUAGCAAGU UAAAAUAAGGC UAGUCCGUUAU CAACUUGAAAA AGUGGCACCGA GUCGGUGCUUU U HBG 1 / 2 first / left gRNA (Pair #6) S. aureus gRNA sequence AAGGCUGGCCA ACCCAUGGGGU UUUAGUACUCU GGAAACAGAAU CUACUAAAACA AGGCAAAAUGC CGUGUUUAUCU CGUCAACUUGU UGGCGAGAUUU U SEQ ID NO: 19 gRNA modifications

[00084] The activity, stability, or other characteristics of gRNAs can be altered through the incorporation of certain modifications. As an example, nucleic acids expressed or delivered transiently may be prone to degradation by, for example, cellular nucleases. Consequently, the gRNAs described herein may contain one or more modified nucleosides or nucleotides that introduce stability with respect to nucleases. While we do not wish to limit ourselves to theory, it is also believed that certain modified gRNAs described herein may exhibit a reduced innate immune response when introduced into cells. Those skilled in the art will be aware of certain cellular responses commonly observed in cells, for example, mammalian cells, in response to exogenous nucleic acids, particularly those of viral or bacterial origin.Such responses, which may include the induction of cytokine expression and release and cell death, can be reduced or completely eliminated by the modifications presented in this document. Petition 870250103694, dated 12 / 11 / 2025, pp. 133 / 211 36 / 97

[00085] Certain exemplary modifications discussed in this section may be included at any position within a gRNA sequence, including, without limitation, at or near the 5' end (e.g., within 1-10, 1-5, or 1-2 nucleotides from the 5' end) and / or at or near the 3' end (e.g., within 1-10, 1-5, or 1-2 nucleotides from the 3' end). In some cases, the modifications are positioned within functional motifs, such as the repeat-antirepeat duplex of a Cas9 gRNA, a stem-loop structure of a Cas9 or Cpf1 gRNA, and / or a target domain of a gRNA.

[00086] As an example, the 5' end of a gRNA may include a eukaryotic mRNA cap structure or cap analog (e.g., a G(5)ppp(5)G cap analog, an m7G(5)ppp(5)G cap analog, or an anti-reverse 3'-O-Me-m7G(5)ppp(5)G (ARCA) cap analog), as shown below: OH OH

[00087] A cap or cap analogue can be included during chemical synthesis or in vitro transcription of gRNA.

[00088] Following similar lines, the 5' end of gRNA may not have a 5' triphosphate group. For example, gRNAs transcribed in vitro can be treated with phosphatase (e.g., using calf intestinal alkaline phosphatase) to remove a 5' triphosphate group.

[00089] Another common modification involves the addition, at the 3' end of a gRNA, of a plurality (e.g., 1-10, 10-20, or 25-200) of adenine (A) residues, termed the polyA tract. The polyA tract can be added to a gRNA during chemical synthesis, after in vitro transcription using a polyadenosine polymerase (e.g., E. coli Poly(A)Polymerase). Petition 870250103694, dated 12 / 11 / 2025, pp. 134 / 211 37 / 97 or in vivo via a polyadenylation sequence, as described in Maeder.

[00090] It should be noted that the modifications described herein may be combined in any suitable manner, for example, a gRNA, whether transcribed in vivo from a DNA vector, or a gRNA transcribed in vitro, may include a 5' cap structure or a cap analog and a 3' polyA tract, or both.

[00091] Guide RNAs can be modified at a 3' terminal U ribose. For example, the two terminal hydroxyl groups of the U ribose can be oxidized to aldehyde groups and a concomitant opening of the ribose ring can provide a modified nucleoside, as shown below: where U can be either unmodified or modified uridine.

[00092] The U-terminal 3' ribose can be modified with a 2'3' cyclic phosphate, as shown below: where U can be either unmodified or modified uridine.

[00093] Guide RNAs may contain 3' nucleotides that can be stabilized against degradation, for example, by incorporating one or more of the modified nucleotides described in this document. In certain embodiments, uridines may be replaced by modified uridines, for example, 5-(2-amino)propyl uridine and 5-bromo uridine, or by any of the modified uridines described in this document; adenosines and guanosines may be replaced by modified adenosines and guanosines. Petition 870250103694, dated 12 / 11 / 2025, pp. 135 / 211 38 / 97 for example, with modifications at position 8, for example, 8-bromoguanosine, or by any of the modified adenosines or guanosines described in this document.

[00094] In certain embodiments, sugar-modified ribonucleotides may be incorporated into gRNA, for example, where the 2' OH group is replaced by a group selected from H, —OR, —R (where R may be, for example, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl or sugar), halo, —SH, —SR (where R may be, for example, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl or sugar), amino (where amino may be, for example, NH2; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, di-heteroarylamino or amino acid); or cyano (—CN). In certain embodiments, the phosphate backbone may be modified as described in this document, for example, with a phosphothioate group (PhTx).In certain embodiments, one or more nucleotides of the gRNA may independently be modified or unmodified nucleotides, including, but not limited to, modified 2'-sugars such as 2'-O-methyl, 2'-O-methoxyethyl, or modified 2'-fluorine, including, for example, 2'-F or 2'-O-methyl, adenosine (A), 2'-F or 2'-O-methyl, cytidine (C), 2'-F or 2'-O-methyl, uridine (U), 2'-F or 2'-O-methyl, thymidine (T), 2'-F or 2'-O-methyl, guanosine (G), 2'-O-methoxyethyl-5-methyluridine (Teo), 2'-O-methoxyethyladenosine (Aeo), 2'-O-methoxyethyl-5-methylcytidine (m5Ceo) and any combinations thereof.

[00095] Guide RNAs may also include locked nucleic acids (LNAs), in which the 2' OH group may be connected, for example, by a C1-6 alkylene or C1-6 heteroalkylene bridge, to the 4' carbon of the same ribose sugar. Any suitable moiety may be used to provide such bridges, including, without limitation, methylene, propylene, ether or amino bridges; O-amino (where amino may be, for example, NH2; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino or di Petition 870250103694, dated 12 / 11 / 2025, pp. 136 / 211 39 / 97 heteroarylamino, ethylenediamine or polyamino) and aminoalkoxy or O(CH2)n-amino (where amino can be, for example, NH2; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino or di-heteroarylamino, ethylenediamine or polyamino).

[00096] In certain embodiments, a gRNA may include a modified nucleotide that is multicyclic (e.g., tricyclic; and “unlocked” forms, such as glycol nucleic acid (GNA) (e.g., R-GNA or SGNA, where ribose is replaced by glycol units linked by phosphodiester bonds), or threose nucleic acid (TNA, where ribose is replaced by αL-threofuranosyl-(3'^2')).

[00097] Generally, gRNAs include the ribose sugar group, which is a 5-membered ring with an oxygen. Exemplary modified gRNAs may include, without limitation, the substitution of the oxygen in the ribose (e.g., with sulfur (S), selenium (Se), or alkylene, such as, for example, methylene or ethylene); the addition of a double bond (e.g., to replace ribose with cyclopentenyl or cyclohexenyl); contraction of the ribose ring (e.g., to form a 4-membered ring of cyclobutane or oxethane); expansion of the ribose ring (e.g., to form a 6- or 7-membered ring with an additional carbon or heteroatom, such as, for example, anhydrohexitol, altritol, mannitol, cyclohexanyl, cyclohexenyl, and morpholino, which also has a phosphoramidate backbone). Although most changes in sugar analogs are located at the 2' position, other sites are also susceptible to modification, including the 4' position.In certain embodiments, a gRNA comprises a 4'-S, 4'-Se, or 4'-C-aminomethyl-2'-O-Me modification.

[00098] In certain embodiments, deaza nucleotides, for example, 7-deaza-adenosine, can be incorporated into gRNA. In certain embodiments, O and N alkylated nucleotides, for example, N6-methyl adenosine, can be incorporated into gRNA. In certain embodiments, one or more or all Petition 870250103694, dated 12 / 11 / 2025, pp. 137 / 211 40 / 97 the nucleotides in a gRNA are deoxynucleotides.

[00099] In some embodiments, gRNA comprises one or more chemical modifications of a ribonucleotide, a ribonucleotide base, or a phosphodiester bond. In some embodiments, the one or more chemical modifications comprise at least one chemically modified phosphodiester bond. In some embodiments, the at least one chemically modified phosphodiester bond is a phosphorothioate bond. [000100] In some embodiments, the gRNA comprises three phosphorothioate linkages at the 5-terminus of the gRNA. In some embodiments, the gRNA comprises two phosphorothioate linkages at the 3-terminus of the gRNA. In some embodiments, the gRNA comprises a 2' OMe chemical modification at the 3' term of the gRNA. Exemplary target sequences and gRNAs [000101] In some embodiments, a gRNA comprises a target sequence comprising a nucleotide sequence at least 95%, 96%, 97%, 98%, or 99% (or any percentage therebetween) identical to SEQ ID NO: 1. In some embodiments, a gRNA comprises a target sequence comprising a nucleotide sequence of SEQ ID NO: 1. [000102] In some embodiments, a gRNA comprises a target sequence comprising a nucleotide sequence at least 95%, 96%, 97%, 98%, or 99% (or any percentage therebetween) identical to SEQ ID NO: 3. In some embodiments, a gRNA comprises a target sequence comprising a nucleotide sequence of SEQ ID NO: 3. [000103] In some embodiments, a gRNA comprises a target sequence comprising a nucleotide sequence at least 95%, 96%, 97%, 98%, or 99% (or any percentage therebetween) identical to SEQ ID NO: 5. In some embodiments, a gRNA comprises a target sequence comprising a nucleotide sequence of SEQ ID NO: 5. Petition 870250103694, dated 12 / 11 / 2025, pp. 138 / 211 41 / 97 [000104] In some embodiments, a gRNA comprises a target sequence comprising a nucleotide sequence at least 95%, 96%, 97%, 98%, or 99% (or any percentage therebetween) identical to SEQ ID NO: 7. In some embodiments, a gRNA comprises a target sequence comprising a nucleotide sequence of SEQ ID NO: 7. [000105] In some embodiments, a gRNA comprises a target sequence comprising a nucleotide sequence at least 95%, 96%, 97%, 98%, or 99% (or any percentage therebetween) identical to SEQ ID NO: 9. In some embodiments, a gRNA comprises a target sequence comprising a nucleotide sequence of SEQ ID NO: 9. [000106] In some embodiments, a gRNA comprises a target sequence comprising a nucleotide sequence at least 95%, 96%, 97%, 98%, or 99% (or any percentage therebetween) identical to SEQ ID NO: 11. In some embodiments, a gRNA comprises a target sequence comprising a nucleotide sequence of SEQ ID NO: 11. [000107] In some embodiments, a gRNA comprises a target sequence comprising a nucleotide sequence at least 95%, 96%, 97%, 98%, or 99% (or any percentage therebetween) identical to SEQ ID NO: 13. In some embodiments, a gRNA comprises a target sequence comprising a nucleotide sequence of SEQ ID NO: 13. [000108] In some embodiments, a gRNA comprises a target sequence comprising a nucleotide sequence at least 95%, 96%, 97%, 98%, or 99% (or any percentage therebetween) identical to SEQ ID NO: 15. In some embodiments, a gRNA comprises a target sequence comprising a nucleotide sequence of SEQ ID NO: 15. Petition 870250103694, dated 12 / 11 / 2025, pp. 139 / 211 42 / 97 [000109] In some embodiments, a gRNA comprises a target sequence comprising a nucleotide sequence at least 95%, 96%, 97%, 98%, or 99% (or any percentage therebetween) identical to SEQ ID NO: 17. In some embodiments, a gRNA comprises a target sequence comprising a nucleotide sequence of SEQ ID NO: 17. Example gRNA sequences [000110] In some embodiments, a gRNA comprises a nucleotide sequence that is at least 95%, 96%, 97%, 98%, or 99% (or any percentage therebetween) identical to SEQ ID NO: 2. In some embodiments, a gRNA comprises a nucleotide sequence of SEQ ID NO: 2. [000111] In some embodiments, a gRNA comprises a nucleotide sequence that is at least 95%, 96%, 97%, 98%, or 99% (or any percentage therebetween) identical to SEQ ID NO: 4. In some embodiments, a gRNA comprises a nucleotide sequence of SEQ ID NO: 4. [000112] In some embodiments, a gRNA comprises a nucleotide sequence that is at least 95%, 96%, 97%, 98%, or 99% (or any percentage therebetween) identical to SEQ ID NO: 6. In some embodiments, a gRNA comprises a nucleotide sequence of SEQ ID NO: 6. [000113] In some embodiments, a gRNA comprises a nucleotide sequence that is at least 95%, 96%, 97%, 98%, or 99% (or any percentage therebetween) identical to SEQ ID NO: 8. In some embodiments, a gRNA comprises a nucleotide sequence of SEQ ID NO: 8. [000114] In some embodiments, a gRNA comprises a Petition 870250103694, dated 12 / 11 / 2025, pages 140 / 211 43 / 97 nucleotide sequence at least 95%, 96%, 97%, 98%, or 99% (or any percentage therebetween) identical to SEQ ID NO: 10. In some embodiments, a gRNA comprises a nucleotide sequence of SEQ ID NO: 10. [000115] In some embodiments, a gRNA comprises a nucleotide sequence that is at least 95%, 96%, 97%, 98%, or 99% (or any percentage therebetween) identical to SEQ ID NO: 12. In some embodiments, a gRNA comprises a nucleotide sequence of SEQ ID NO: 12. [000116] In some embodiments, a gRNA comprises a nucleotide sequence that is at least 95%, 96%, 97%, 98%, or 99% (or any percentage therebetween) identical to SEQ ID NO: 14. In some embodiments, a gRNA comprises a nucleotide sequence of SEQ ID NO: 14. [000117] In some embodiments, a gRNA comprises a nucleotide sequence that is at least 95%, 96%, 97%, 98%, or 99% (or any percentage therebetween) identical to SEQ ID NO: 16. In some embodiments, a gRNA comprises a nucleotide sequence of SEQ ID NO: 16. [000118] In some embodiments, a gRNA comprises a nucleotide sequence that is at least 95%, 96%, 97%, 98%, or 99% (or any percentage therebetween) identical to SEQ ID NO: 19. In some embodiments, a gRNA comprises a nucleotide sequence of SEQ ID NO: 19. Example gRNA compositions [000119] In certain disclosure compositions, the composition comprises a first gRNA (also called left gRNA) and a second gRNA (also called right gRNA). The first gRNA may Petition 870250103694, dated 12 / 11 / 2025, pp. 141 / 211 44 / 97 understands a first target sequence. The second gRNA can understand a second target sequence. [000120] In some embodiments, the composition comprises a first gRNA comprising a first target sequence comprising a nucleotide sequence of SEQ ID NO: 1 and a second gRNA comprising a second target sequence comprising a nucleotide sequence of SEQ ID NO: 3. In some embodiments, the composition comprises a first gRNA comprising a nucleotide sequence of SEQ ID NO: 2 and a second gRNA comprising a nucleotide sequence of SEQ ID NO: 4. [000121] In some embodiments, the composition comprises a first gRNA comprising a first target sequence comprising a nucleotide sequence of SEQ ID NO: 5 and a second gRNA comprising a second target sequence comprising a nucleotide sequence of SEQ ID NO: 3. In some embodiments, the composition comprises a first gRNA comprising a nucleotide sequence of SEQ ID NO: 6 and a second gRNA comprising a nucleotide sequence of SEQ ID NO: 4. [000122] In some embodiments, the composition comprises a first gRNA comprising a first target sequence comprising a nucleotide sequence of SEQ ID NO: 7 and a second gRNA comprising a second target sequence comprising a nucleotide sequence of SEQ ID NO: 3. In some embodiments, the composition comprises a first gRNA comprising a nucleotide sequence of SEQ ID NO: 8 and a second gRNA comprising a nucleotide sequence of SEQ ID NO: 4. [000123] In some embodiments, the composition comprises a first gRNA comprising a first target sequence. Petition 870250103694, dated 12 / 11 / 2025, pp. 142 / 211 45 / 97 comprising a nucleotide sequence of SEQ ID NO: 9 and a second gRNA comprising a second target sequence comprising a nucleotide sequence of SEQ ID NO: 11. In some embodiments, the composition comprises a first gRNA comprising a nucleotide sequence of SEQ ID NO: 10 and a second gRNA comprising a nucleotide sequence of SEQ ID NO: 12. [000124] In some embodiments, the composition comprises a first gRNA comprising a first target sequence comprising a nucleotide sequence of SEQ ID NO: 13 and a second gRNA comprising a second target sequence comprising a nucleotide sequence of SEQ ID NO: 11. In some embodiments, the composition comprises a first gRNA comprising a nucleotide sequence of SEQ ID NO: 14 and a second gRNA comprising a nucleotide sequence of SEQ ID NO: 12. [000125] In some embodiments, the composition comprises a first gRNA comprising a first target sequence comprising a nucleotide sequence of SEQ ID NO: 7 and a second gRNA comprising a second target sequence comprising a nucleotide sequence of SEQ ID NO: 11. In some embodiments, the composition comprises a first gRNA comprising a nucleotide sequence of SEQ ID NO: 19 and a second gRNA comprising a nucleotide sequence of SEQ ID NO: 12. [000126] In some embodiments, the composition comprises a first gRNA comprising a first target sequence comprising a nucleotide sequence of SEQ ID NO: 15 and a second gRNA comprising a second target sequence comprising a nucleotide sequence of SEQ ID NO: 3. In some embodiments, the composition comprises a first gRNA comprising a sequence of Petition 870250103694, dated 12 / 11 / 2025, pp. 143 / 211 46 / 97 nucleotides of SEQ ID NO: 16 and a second gRNA comprising a nucleotide sequence of SEQ ID NO: 4. [000127] In some embodiments, the composition comprises a first gRNA comprising a first target sequence comprising a nucleotide sequence of SEQ ID NO: 17 and a second gRNA comprising a second target sequence comprising a nucleotide sequence of SEQ ID NO: 3. In some embodiments, the composition comprises a first gRNA comprising a nucleotide sequence of SEQ ID NO: 18 and a second gRNA comprising a nucleotide sequence of SEQ ID NO: 4. Example Compositions of Cas-CLOVER and gRNA [000128] Gene editing compositions, including CasCLOVER, and methods of using these compositions for gene editing are described in detail in PCT Application Numbers PCT / US2016 / 037922, PCT / US2018 / 066941, PCT / US2017 / 054799, U.S. Patent Publications Nos. 2017 / 0107541, 2017 / 0114149, 2018 / 0187185 and U.S. Patent No. 10,415,024, each of which is incorporated herein by reference in its entirety for examples of gene-editing compositions that may be used in the methods disclosed herein. Exemplary gene-editing compositions, including Cas-CLOVER, and methods of using these compositions for gene editing are described herein. [000129] In certain disclosure compositions, the composition comprises a first gRNA (also called left gRNA), a first fusion protein or a first polynucleotide encoding the first fusion protein (e.g., Cas-Clover), a second gRNA (also called right gRNA), and a second fusion protein or a second polynucleotide encoding a second fusion protein (e.g., Cas-Clover). Petition 870250103694, dated 12 / 11 / 2025, pp. 144 / 211 47 / 97 Clover). The first gRNA comprises a first target sequence. The second gRNA comprises a second target sequence. [000130] In some embodiments, the first gRNA and the first fusion protein are complexed at the 5' end of the target DNA to be modified. In some embodiments, the second gRNA and the second fusion protein are complexed at the 3' end of the target DNA to be modified. A schematic diagram of the complexed composition with a target DNA is shown in FIGURE 7. [000131] In some embodiments, the first fusion protein, the second fusion protein, or both the first and second fusion proteins, comprise a dCas9 derived from a Cas9 polypeptide of S. pyogenes. In some embodiments, the first fusion protein, the second fusion protein, or both the first and second fusion proteins, comprise a dCas9 derived from a Cas9 polypeptide of S. aureus. Exemplary compositions of the disclosure are shown in Table 2. Table 2. Example Compositions of the Disclosure Name of the composition First (left) gRNA Template First (left) gRNA Full sequence First (left) Cas-Clover Second (right) gRNA Template Second (right) gRNA Full sequence Second (right) CasClover Pair #1 SEQ ID NO: 1 SEQ ID NO: 2 SEQ ID NO: 39 SEQ ID NO: 3 SEQ ID NO: 4 SEQ ID NO: 39 Pair #2 SEQ ID NO: 5 SEQ ID NO: 6 SEQ ID NO: 39 SEQ ID NO: 3 SEQ ID NO: 4 SEQ ID NO: 39 Pair #3 SEQ ID NO: 7 SEQ ID NO: 8 SEQ ID NO: 41 SEQ ID NO: 3 SEQ ID NO: 4 SEQ ID NO: 41 Pair #4 SEQ ID NO: 9 SEQ ID NO: 10 SEQ ID NO: 39 SEQ ID NO: 11 SEQ ID NO: 12 SEQ ID NO: 42 Pair #5 SEQ ID NO: 13 SEQ ID NO: 14 SEQ ID NO: 42 SEQ ID NO: 11 SEQ ID NO: 12 SEQ ID NO: 42 Pair #6 SEQ ID NO: 7 SEQ ID NO: 19 SEQ ID NO: 42 SEQ ID NO: 11 SEQ ID NO: 12 SEQ ID NO: 42 Pair #7 SEQ ID NO: 15 SEQ ID NO: 16 SEQ ID NO: 41 SEQ ID NO: 3 SEQ ID NO: 4 SEQ ID NO: 41 Pair #8 SEQ ID NO: 17 SEQ ID NO: 18 SEQ ID NO: 41 SEQ ID NO: 3 SEQ ID NO: 4 SEQ ID NO: 41 Petition 870250103694, dated 12 / 11 / 2025, pages 145 / 211 48 / 97 [000132] In some embodiments, the composition comprises a first gRNA comprising a nucleotide sequence of SEQ ID NO: 2, a first fusion protein comprising the polypeptide sequence of SEQ ID NO: 39, a second gRNA comprising a nucleotide sequence of SEQ ID NO: 4, and a second fusion protein comprising the polypeptide sequence of SEQ ID NO: 39. [000133] In some embodiments, the composition comprises a first gRNA comprising a nucleotide sequence of SEQ ID NO: 6, a first fusion protein comprising the polypeptide sequence of SEQ ID NO: 39, a second gRNA comprising a nucleotide sequence of SEQ ID NO: 4, and a second fusion protein comprising the polypeptide sequence of SEQ ID NO: 39. [000134] In some embodiments, the composition comprises a first gRNA comprising a nucleotide sequence of SEQ ID NO: 8, a first fusion protein comprising the polypeptide sequence of SEQ ID NO: 41, a second gRNA comprising a nucleotide sequence of SEQ ID NO: 4, and a second fusion protein comprising the polypeptide sequence of SEQ ID NO: 41. [000135] In some embodiments, the composition comprises a first gRNA comprising a nucleotide sequence of SEQ ID NO: 10, a first fusion protein comprising the polypeptide sequence of SEQ ID NO: 39, a second gRNA comprising a nucleotide sequence of SEQ ID NO: 12, and a second fusion protein comprising the polypeptide sequence of SEQ ID NO: 42. [000136] In some embodiments, the composition comprises a first gRNA comprising a nucleotide sequence of SEQ ID NO: 14, a first fusion protein comprising the polypeptide sequence of SEQ ID NO: 42, a second gRNA comprising a Petition 870250103694, dated 12 / 11 / 2025, pp. 146 / 211 49 / 97 nucleotide sequence of SEQ ID NO: 12 and a second fusion protein comprising the polypeptide sequence of SEQ ID NO: 42. [000137] In some embodiments, the composition comprises a first gRNA comprising a nucleotide sequence of SEQ ID NO: 19, a first fusion protein comprising the polypeptide sequence of SEQ ID NO: 42, a second gRNA comprising a nucleotide sequence of SEQ ID NO: 12, and a second fusion protein comprising the polypeptide sequence of SEQ ID NO: 42. [000138] In some embodiments, the composition comprises a first gRNA comprising a nucleotide sequence of SEQ ID NO: 16, a first fusion protein comprising the polypeptide sequence of SEQ ID NO: 41, a second gRNA comprising a nucleotide sequence of SEQ ID NO: 4, and a second fusion protein comprising the polypeptide sequence of SEQ ID NO: 41. [000139] In some embodiments, the composition comprises a first gRNA comprising a nucleotide sequence of SEQ ID NO: 18, a first fusion protein comprising the polypeptide sequence of SEQ ID NO: 41, a second gRNA comprising a nucleotide sequence of SEQ ID NO: 4, and a second fusion protein comprising the polypeptide sequence of SEQ ID NO: 41. Delivery of gRNAs and Gene Editing Composites [000140] Gene editing tools can also be delivered to cells using one or more poly(histidine)-based micelles. Poly(histidine) (e.g., poly(L-histidine)) is a pH-sensitive polymer due to the imidazole ring providing a lone pair of electrons on the unsaturated nitrogen. That is, poly(histidine) possesses amphoteric properties through protonation-deprotonation. In particular, at certain pHs, triblock copolymers containing poly(histidine) can assemble into a micelle. Petition 870250103694, dated 12 / 11 / 2025, pp. 147 / 211 50 / 97 with positively charged poly(histidine) units on the surface, thus allowing complexation with negatively charged gene-editing molecule(s). The use of these nanoparticles to bind and release proteins and / or nucleic acids in a pH-dependent manner can provide an efficient and selective mechanism for achieving a desired genetic modification. In particular, this micelle-based delivery system provides substantial flexibility regarding the materials carried, as well as a large payload capacity and targeted payload release from the nanoparticles. In one example, site-specific cleavage of double-stranded DNA is enabled by delivering a nuclease using poly(histidine)-based micelles.Without wanting to limit ourselves to a specific theory, it is believed that, in micelles formed by various triblock copolymers, the hydrophobic blocks aggregate to form a core, leaving the hydrophilic blocks and the poly(histidine) blocks at the ends to form one or more surrounding layers. [000141] In one aspect, the disclosure provides triblock copolymers composed of a hydrophilic block, a hydrophobic block, and a charged block. In some aspects, the hydrophilic block may be poly(ethylene oxide) (PEO) and the charged block may be poly(L-histidine). An example of a triblock copolymer that can be used is a PEO-b-PLA-b-PHIS, with varying numbers of repeating units in each block, depending on the design. [000142] Diblock copolymers that can be used as intermediates for the manufacture of triblock copolymers may have hydrophilic biocompatible poly(ethylene oxide) (PEO), which is chemically synonymous with PEG, coupled to various hydrophobic aliphatic poly(anhydrides), poly(nucleic acids), poly(esters), poly(orthoesters), poly(peptides), poly(phosphazenes) and poly(saccharides), including, but not limited to, poly(lactide) (PLA), poly(glycolide) (PLGA), poly(lactic-co-glycolic acid) (PLGA), poly(ε-caprolactone) (PCL) and Petition 870250103694, dated 12 / 11 / 2025, pp. 148 / 211 51 / 97 poly(trimethylene carbonate) (PTMC). Polymeric micelles composed of 100% PEGylated surfaces possess enhanced in vitro chemical stability, increased in vivo bioavailability, and prolonged blood circulatory half-lives. [000143] Polymeric vesicles, polymersomes and micelles based on poly(histidine), including those comprising triblock copolymers, and methods for manufacturing them, are described in further detail in U.S. Patents Nos. 7,217,427; 7,868,512; 6,835,394; 8,808,748; 10,456,452; U.S. Publications Nos. 2014 / 0363496; 2017 / 0000743; and 2019 / 0255191; and PCT Publication No. WO 2019 / 126589, each of which is incorporated herein by reference in its entirety for examples of polymers that may be used to deliver the compositions disclosed herein. [000144] Genetic editing compositions (e.g., Mutant Cas-Clover cells can also be delivered to cells using one or more lipid nanoparticle compositions and methods for producing them, as described in PCT Publications WO 2022 / 182792 and WO 2023 / 141576, each of which is incorporated herein by reference in its entirety for examples of lipid nanoparticles that can be used to deliver the gene-editing compositions disclosed herein. [000145] In some respects, the composition is encapsulated in at least one lipid nanoparticle comprising: about 40.75% of a terpene lipidoid compound per mol, about 51.75% of cholesterol per mol, about 5% of DOPC per mol and about 2.5% of DMG-PEG2000 per mol, wherein a polynucleotide encoding the mutant Cas-Clover is an RNA molecule, and wherein the ratio of the lipid molecule to RNA in at least one nanoparticle is about 120:1 (w / w). Petition 870250103694, dated 12 / 11 / 2025, pp. 149 / 211 52 / 97 [000146] In some respects, the terpene lipidoid compound is HMA-404: [000147] Thus, in some respects, the gene-editing composition is encapsulated in at least one lipid nanoparticle comprising: about 40.75% HMA-404 per mol, about 51.75% cholesterol per mol, about 5% DOPC per mol and about 2.5% DMGPEG2000 per mol, wherein one polynucleotide encoding the Cas-Clover mutant is an RNA molecule, and wherein the lipid to RNA molecule ratio in at least one nanoparticle is about 120:1 (w / w). [000148] In some respects, the composition is encapsulated in at least one lipid nanoparticle comprising: about 54 mol% SS-OP, about 35 mol% cholesterol, about 5 mol% DOPC, about 5 mol% DSPC and about 1 mol% DMG-PEG2000. The lipid to nucleic acid ratio in the nanoparticles was about 100:1 (w / w) and the total lipid was 25 mM. CELLS AND MODIFIED CELLS FROM THE DISCLOSURE [000149] The cells and modified cells of the disclosure may be mammalian cells. The cells and modified cells are human cells. In some embodiments, the cells may comprise hematopoietic progenitor cells (HPCs). In some embodiments, the cells may comprise hematopoietic stem cells (HSCs). In some embodiments, the cells are hematopoietic stem and precursor cells (HSPCs). In some embodiments, the HSPCs are capable of differentiating into Petition 870250103694, dated 12 / 11 / 2025, pages 150 / 211 53 / 97 erythroid progenitor cells. In certain embodiments, at least a portion of the cell plurality may belong to an erythroid lineage. In some embodiments, HSPCs are capable of differentiating into an erythroid progenitor cell. [000150] Cells that have been altered ex vivo in accordance with this disclosure may be manipulated (e.g., expanded, passaged, frozen, differentiated, dedifferentiated, transduced with a transgene, etc.) before delivery to an individual. The cells are, in various ways, delivered to an individual from whom they are obtained (in an autologous transplant) or to an immunologically distinct recipient from a donor of the cells (in an allogeneic transplant). [000151] In some embodiments, an autologous transplant includes the steps of obtaining, from the individual, a plurality of cells circulating in the peripheral blood or bone marrow or other tissue (e.g., spleen, skin, etc.), and manipulating these cells for enrichment of erythroid lineage cells (e.g., by induction to generate iPSCs, purification of cells expressing certain cell surface markers such as CD34, CD90, CD49f, and / or not expressing surface markers characteristic of non-erythroid lineages such as CD10, CD14, CD38, etc.). The cells are optionally or additionally expanded, transduced with a transgene, exposed to a cytokine or other peptide or small molecule agent, and / or frozen / thawed before transduction with a genome editing system targeting the BCL11A gene or the target sequence of the HBG1 and / or HBG2 promoter.The genome editing system can be implemented or delivered to cells in any suitable format, including as a ribonucleoprotein complex, as separate protein and nucleic acid components, and / or as nucleic acids encoding the genome editing system components. Petition 870250103694, dated 12 / 11 / 2025, pages 151 / 211 54 / 97 [000152] After delivery of the genome editing system, the cells are optionally manipulated, for example, to enrich HSCs and / or erythroid lineage cells and / or edited cells, to expand them, freeze / thaw them, or otherwise prepare them for return to the individual. The edited cells are then returned to the individual, for example, into the circulatory system via intravenous delivery or delivery, or into a solid tissue such as bone marrow. Modified Cells of Disclosure [000153] Disclosure provides a method for modifying a cell population, comprising contacting the cell population with the disclosure compositions (e.g., first CasClover fusion protein and first gRNA, and the compositions of the second CasClover fusion protein and the second gRNA), wherein the first gRNA forms a complex with the first target sequence and the first fusion protein, and the second gRNA forms a complex with the second target sequence and the second fusion protein, thus generating an insertion or deletion (indel) between the first target sequence and the second target sequence and producing a modified cell population. In some embodiments, the indel is generated in the BCL11A gene, in the HMG1 promoter region, in the HMG2 promoter region, or in a combination thereof. In some embodiments, the indel causes inactivation of the BCL11A gene. [000154] In some embodiments, the disclosure refers to compositions that include a plurality of cells generated by the method disclosed above, in which at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the cells include an indel between the first target sequence and the second target sequence. In some embodiments, the disclosure refers to compositions that include a plurality of cells generated by the method disclosed above, in which at least 20%, 30%, 40%, 50%, 60%, 70%, 80% Petition 870250103694, dated 12 / 11 / 2025, pp. 152 / 211 55 / 97 or 90% of the cells include an indel in the BCL11A gene. In some embodiments, the disclosure refers to compositions that include a plurality of cells generated by the method disclosed above, in which at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the cells include an indel in the HMG1 promoter region. In some embodiments, the disclosure refers to compositions that include a plurality of cells generated by the method disclosed above, in which at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the cells include an indel in the HMG2 promoter region. [000155] In certain embodiments, cell plurality can be characterized by an increased level of fetal hemoglobin (HbF) expression compared to unmodified cell plurality. In certain embodiments, the fetal hemoglobin level can be increased by at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%. In certain embodiments, the fetal hemoglobin level can be increased by about 1-fold to about 10-fold. In certain embodiments, the fetal hemoglobin level can be increased by about 4-fold to about 9-fold. In certain realizations, the fetal hemoglobin level can be increased by approximately 1 to 2 times, approximately 2 to 3 times, approximately 3 to 4 times, approximately 4 to 5 times, approximately 5 to 6 times, approximately 6 to 7 times, approximately 7 to 8 times, approximately 8 to 9 times, and approximately 9 to 10 times.In certain realizations, the fetal hemoglobin level can be increased by approximately 1-fold, approximately 2-fold, approximately 3-fold, approximately 4-fold, approximately 5-fold, approximately 6-fold, approximately 7-fold, approximately 8-fold, approximately 9-fold, or approximately 10-fold. [000156] In certain embodiments, cell plurality can be characterized by an increased level of gamma globulin expression compared to unmodified cell plurality. In certain embodiments, the gamma globulin level can be increased by at least 20%, 30%, 40%, Petition 870250103694, dated 12 / 11 / 2025, pp. 153 / 211 56 / 97 50%, 60%, 70%, 80%, or 90%. In certain embodiments, the gamma globulin level may be increased by about 1 to about 10 times. In certain embodiments, the gamma globulin level may be increased by about 4 to about 9 times. In certain embodiments, the gamma globulin level may be increased by about 1 to about 2 times, about 2 to about 3 times, about 3 to about 4 times, about 4 to about 5 times, about 5 to about 6 times, about 6 to about 7 times, about 7 to about 8 times, about 8 to about 9 times, about 9 to about 10 times. In some realizations, the gamma globulin level can be increased by about 1 time, about 2 times, about 3 times, about 4 times, about 5 times, about 6 times, about 7 times, about 8 times, about 9 times, or about 10 times. [000157] Dissemination cells and modified immune cells can be autologous cells or allogeneic cells. Allogeneic cells are engineered to prevent adverse graft reactions after administration to an individual. Allogeneic cells can be of any cell type. Allogeneic cells can be stem cells or derived from stem cells. Allogeneic cells can be differentiated somatic cells. [000158] In certain respects, the cells of the present disclosure are modified to recombinantly express dihydrofolate reductase (DHFR), which advantageously makes the cells resistant to methotrexate (MTX). MTX-resistant cells can be used in treatment methods for an individual in need of MTX, in combination with subsequent administration of MTX, to eliminate activated T cells and NK cells that target the modified cells or therapeutic cells, thereby increasing the persistence and in vivo efficacy of the modified cells. Petition 870250103694, dated 12 / 11 / 2025, pp. 154 / 211 57 / 97 Formulations, Dosages and Methods of Administration [000159] Genome editing systems, or cells altered or manipulated by such systems, may be administered to individuals by any suitable mode or route, whether local or systemic. Systemic modes of administration include oral and parenteral routes. Parenteral routes include, by way of example, intravenous, intramedullary, intra-arterial, intramuscular, intradermal, subcutaneous, intranasal, and intraperitoneal routes. Systemically administered components may be modified or formulated to target, for example, HSCs, hematopoietic stem / progenitor cells, or erythroid progenitor or precursor cells. [000160] Local administration methods include, for example, intramedullary injection into the trabecular bone or intrafemoral injection into the medullary space and infusion into the portal vein. In certain embodiments, significantly smaller amounts of the components (compared to systemic approaches) can exert an effect when administered locally (e.g., directly into the bone marrow) compared to when administered systemically (e.g., intravenously). Local administration methods can reduce or eliminate the incidence of potentially toxic side effects that can occur when therapeutically effective amounts of a component are administered systemically. [000161] Administration can be provided as a periodic bolus (e.g., intravenously) or as a continuous infusion from an internal or external reservoir (e.g., from an intravenous bag or implantable pump). Components can be administered locally, for example, by continuous release from a sustained drug delivery device. [000162] In addition, the components can be formulated Petition 870250103694, dated 12 / 11 / 2025, pages 155 / 211 58 / 97 to allow release over an extended period. A release system may include a matrix of a biodegradable material or a material that releases the incorporated components by diffusion. The components may be distributed homogeneously or heterogeneously within the release system. A variety of release systems may be useful; however, the choice of the appropriate system will depend on the release rate required by a specific application. Degradable and non-degradable release systems may be used. Suitable release systems include polymers and polymeric matrices, non-polymeric matrices or excipients, and inorganic and organic diluents such as, but not limited to, calcium carbonate and sugar (e.g., trehalose). Release systems may be natural or synthetic.However, synthetic release systems are preferred because they are generally more reliable, more reproducible, and produce more defined release profiles. The release system material can be selected so that components with different molecular weights are released by diffusion or degradation of the material. [000163] Representative synthetic and biodegradable polymers include, for example: polyamides, such as poly(amino acids) and poly(peptides); polyesters, such as poly(lactic acid), poly(glycolic acid), poly(lactic-co-glycolic acid) and poly(caprolactone); poly(anhydrides); polyorthoesters; polycarbonates; and chemical derivatives thereof (substitutions, additions of chemical groups, for example, alkyl, alkylene, hydroxylations, oxidations and other modifications routinely made by those skilled in the art), copolymers and mixtures thereof. Representative synthetic and non-degradable polymers include, for example: polyethers, such as poly(ethylene oxide), poly(ethylene glycol) and poly(tetramethylene oxide); Vinyl polymers, polyacrylates and polymethacrylates, such as methyl, ethyl, other alkyls, hydroxyethyl methacrylate, acrylic and methacrylic acids, and others, such as poly(vinyl alcohol), Petition 870250103694, dated 12 / 11 / 2025, pp. 156 / 211 59 / 97 poly(vinylpyrrolidone) and poly(vinyl acetate); poly(urethanes); cellulose and its derivatives, such as alkyl, hydroxyalkyl, ethers, esters, nitrocellulose and various cellulose acetates; polysiloxanes; and any chemical derivatives thereof (substitutions, additions of chemical groups, for example, alkyl, alkylene, hydroxylations, oxidations and other modifications routinely made by those skilled in the art), copolymers and mixtures thereof. [000164] Poly(lactide-co-glycolide) microspheres can also be used. Typically, the microspheres are composed of a polymer of lactic acid and glycolic acid, which are structured to form hollow spheres. The spheres can be approximately 15 to 30 micrometers in diameter and can be loaded with the components described in this document. In some embodiments, the genome editing systems, system components, and / or nucleic acid coding system components are delivered with a block copolymer, such as a poloxamer or a poloxamine. Methods of Using the Compositions for Dissemination [000165] The disclosure provides for the use of a disclosed composition or pharmaceutical composition for the treatment of a disease or disorder in a cell, tissue, organ, animal or individual, as known in the art or as described herein, using the disclosed compositions and pharmaceutical compositions, for example, by administering or bringing the cell, tissue, organ, animal or individual into contact with an effective therapeutic amount of the composition or pharmaceutical composition. In one aspect, the individual is a mammal. Preferably, the individual is human. The terms individual and patient are used interchangeably herein. [000166] Disclosure provides a method for modulating or treating at least one disease or disorder in a cell, tissue, organ, animal Petition 870250103694, dated 12 / 11 / 2025, pp. 157 / 211 60 / 97 or individual. Preferably, the malignant disease is a beta-hemoglobinopathy. Non-limiting examples of beta-hemoglobinopathies include sickle cell anemia and beta-thalassemia. [000167] Disclosure compositions may be used to treat a disease or disorder by using a therapeutic transgene encoding an exogenous nucleic acid sequence or exogenous amino acid sequence. For certain diseases or disorders, the therapeutic transgene may include [Disease] (therapeutic transgene): [Beta-Thalassemia] (HBB T87Q, BCL11A shRNA, IGF2BP1), [Sickle Cell Anemia] (HBB T87Q, BCL11A shRNA, IGF2BP1. [000168] Genome editing systems, or cells altered or manipulated by such systems, may be administered to individuals by any suitable mode or route, whether local or systemic. Systemic modes of administration include oral and parenteral routes. Parenteral routes include, by way of example, intravenous, intramedullary, intra-arterial, intramuscular, intradermal, subcutaneous, intranasal, and intraperitoneal routes. Systemically administered components may be modified or formulated to target, for example, HSCs, hematopoietic stem / progenitor cells, or erythroid progenitor or precursor cells. [000169] Local administration methods include, for example, intramedullary injection into the trabecular bone or intrafemoral injection into the medullary space and infusion into the portal vein. In certain embodiments, significantly smaller amounts of the components (compared to systemic approaches) can exert an effect when administered locally (e.g., directly into the bone marrow) compared to when administered systemically (e.g., intravenously). Local administration methods can reduce or eliminate the incidence of potentially toxic side effects that can occur when therapeutically effective amounts of a component are administered systemically. Petition 870250103694, dated 12 / 11 / 2025, pp. 158 / 211 61 / 97 [000170] Administration can be provided as a periodic bolus (e.g., intravenously) or as a continuous infusion from an internal or external reservoir (e.g., from an intravenous bag or implantable pump). Components can be administered locally, for example, by continuous release from a sustained drug delivery device. [000171] In addition, the components can be formulated to allow release over an extended period. A release system may include a matrix of a biodegradable material or a material that releases the incorporated components by diffusion. The components may be distributed homogeneously or heterogeneously within the release system. A variety of release systems may be useful; however, the choice of the appropriate system will depend on the release rate required by a specific application. Degradable and non-degradable release systems may be used. Suitable release systems include polymers and polymeric matrices, non-polymeric matrices or excipients, and inorganic and organic diluents such as, but not limited to, calcium carbonate and sugar (e.g., trehalose). Release systems may be natural or synthetic.However, synthetic release systems are preferred because they are generally more reliable, more reproducible, and produce more defined release profiles. The release system material can be selected so that components with different molecular weights are released by diffusion or degradation of the material. [000172] Representative synthetic and biodegradable polymers include, for example: polyamides, such as poly(amino acids) and poly(peptides); polyesters, such as poly(lactic acid), poly(glycolic acid), poly(lactic-co-glycolic acid) and poly(caprolactone); poly(anhydrides); polyorthoesters; polycarbonates; and chemical derivatives thereof Petition 870250103694, dated 12 / 11 / 2025, pp. 159 / 211 62 / 97 (substitutions, additions of chemical groups, for example, alkyl, alkylene, hydroxylations, oxidations and other modifications routinely made by those skilled in the art), copolymers and mixtures thereof.Representative synthetic and non-degradable polymers include, for example: polyethers, such as poly(ethylene oxide), poly(ethylene glycol) and poly(tetramethylene oxide); vinyl polymers, polyacrylates and polymethacrylates, such as methyl, ethyl, other alkyls, hydroxyethyl methacrylate, acrylic and methacrylic acids, and others, such as poly(vinyl alcohol), poly(vinyl pyrrolidone) and poly(vinyl acetate); poly(urethanes); cellulose and its derivatives, such as alkyl, hydroxyalkyl, ethers, esters, nitrocellulose and various cellulose acetates; polysiloxanes; and any chemical derivatives thereof (substitutions, additions of chemical groups, for example, alkyl, alkylene, hydroxylations, oxidations and other modifications routinely made by those skilled in the art), copolymers and mixtures thereof. [000173] Poly(lactide-co-glycolide) microspheres can also be used. Typically, the microspheres are composed of a polymer of lactic acid and glycolic acid, which are structured to form hollow spheres. The spheres can be approximately 15 to 30 micrometers in diameter and can be loaded with the components described in this document. In some embodiments, the genome editing systems, system components, and / or nucleic acid coding system components are delivered with a block copolymer, such as a poloxamer or a poloxamine. Definitions [000174] As used throughout the disclosure, the singular forms a, an, and / or include plural referents unless the context clearly indicates otherwise. Thus, for example, reference to a method includes a plurality of such methods, and reference to a dose includes reference to one or more doses and equivalents thereof known by Petition 870250103694, dated 12 / 11 / 2025, pages 160 / 211 63 / 97 technicians in the field, and so on. [000175] The term "about" or "approximately" means within an acceptable range of error for the specific value, as determined by a person skilled in the art, which will depend in part on how the value is measured or determined, for example, the limitations of the measuring system. For example, "about" may mean within 1 or more standard deviations. Alternatively, "about" may mean a range of up to 20%, or up to 10%, or up to 5%, or up to 1% of a given value. Alternatively, particularly with regard to biological systems or processes, the term may mean within an order of magnitude, preferably within 5 times, and more preferably within 2 times, of a value. When specific values ​​are described in the application and claims, unless otherwise indicated, the term "about" meaning "within an acceptable range of error for the specific value" shall be assumed. [000176] Disclosure provides compositions of isolated or substantially purified polynucleotides or proteins. An isolated or purified polynucleotide or protein, or biologically active part thereof, is substantially or essentially free of components that normally accompany or interact with the polynucleotide or protein as found in its naturally occurring environment. Thus, an isolated or purified polynucleotide or protein is substantially free of other cellular material or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. Ideally, an isolated polynucleotide is free of sequences (optimally protein-coding sequences) that naturally flank the polynucleotide (i.e., sequences located at the 5' and 3' ends of the polynucleotide) in the genomic DNA of the organism from which the polynucleotide is derived.For example,. Petition 870250103694, dated 12 / 11 / 2025, pages 161 / 211 64 / 97 In several respects, the isolated polynucleotide may contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, or 0.1 kb of nucleotide sequence that naturally flanks the polynucleotide in the genomic DNA of the cell from which the polynucleotide is derived. A substantially cell-free protein includes protein preparations with less than about 30%, 20%, 10%, 5%, or 1% (by dry weight) of contaminating protein. When the disclosure protein or biologically active part thereof is produced recombinantly, the ideal culture medium contains less than about 30%, 20%, 10%, 5%, or 1% (by dry weight) of chemical precursors or non-protein chemicals of interest. [000177] This disclosure provides fragments and variants of the disclosed DNA sequences and proteins encoded by those DNA sequences. As used throughout this disclosure, the term fragment refers to a portion of the DNA sequence or a portion of the amino acid sequence and therefore to the protein it encodes. Fragments of a DNA sequence comprising coding sequences may encode protein fragments that retain the biological activity of the native protein and therefore DNA recognition or binding activity to a target DNA sequence, as described herein. Alternatively, fragments of a DNA sequence that are useful as hybridization probes generally do not encode proteins that retain biological activity or that do not retain promoter activity.Thus, the fragments of a DNA sequence can vary from at least about 20 nucleotides, about 50 nucleotides, about 100 nucleotides, and up to the full-length polynucleotide of the fragment. [000178] Nucleic acids or dissemination proteins can be constructed by a modular approach, including the pre-assembly of monomeric units and / or repeat units in target vectors that Petition 870250103694, dated 12 / 11 / 2025, pp. 162 / 211 65 / 97 can be subsequently assembled into a final target vector. Disclosure polypeptides can comprise repeating monomers of disclosure and can be constructed by a modular approach, pre-assembling repeating units into target vectors that can be subsequently assembled into a final target vector. Disclosure provides the polypeptide produced by this method as well as nucleic acid sequences encoding these polypeptides. Disclosure provides host organisms and cells comprising nucleic acid sequences encoding the polypeptides produced by this modular approach. [000179] The term antibody is used in its broadest sense and specifically encompasses single monoclonal antibodies (including agonist and antagonist antibodies) and antibody compositions with polyepitope specificity. Also within the scope of this document is the use of analogs, mutants, variants, alleles, homologs, and orthologs, whether natural or synthetic (collectively referred to herein as analogs) of the antibodies described herein. Thus, according to one aspect of this document, the term antibody described herein, in its broadest sense, also encompasses such analogs. Generally, in such analogs, one or more amino acid residues may have been substituted, deleted, and / or added, compared to the antibodies described herein. [000180] The term linkage refers to a non-covalent, sequence-specific interaction between macromolecules (e.g., between a protein and a nucleic acid). Not all components of a linkage interaction need to be sequence-specific (e.g., contacts with phosphate residues in a DNA backbone), as long as the interaction as a whole is sequence-specific. [000181] The term comprising means that the Petition 870250103694, dated 12 / 11 / 2025, pp. 163 / 211 66 / 97 compositions and methods include the elements mentioned, but do not exclude others. "Consisting essentially of," when used to define compositions and methods, means excluding other elements of any essential importance to the combination when used for the intended purpose. Thus, a composition consisting essentially of the elements as defined herein would not exclude residual contaminants or inert carriers. "Consisting of" means excluding more than trace elements of other ingredients and substantial steps of the method. The aspects defined by each of these transitional terms are within the scope of this disclosure. [000182] As used in this document, expression refers to the process by which polynucleotides are transcribed into mRNA and / or the process by which the transcribed mRNA is subsequently translated into peptides, polypeptides, or proteins. If the polynucleotide is derived from genomic DNA, the expression may include the splicing of the mRNA in a eukaryotic cell. [000183] Gene expression refers to the conversion of the information contained in a gene into a gene product. A gene product can be the direct transcriptional product of a gene (e.g., mRNA, tRNA, rRNA, antisense RNA, ribozyme, shRNA, microRNA, structural RNA, or any other type of RNA) or a protein produced by the translation of an mRNA. Gene products also include RNAs that are modified by processes such as capping, polyadenylation, methylation, and editing, and proteins modified by, for example, methylation, acetylation, phosphorylation, ubiquitination, ADPribosylation, myristylation, and glycosylation. [000184] Modulation or regulation of gene expression refers to an alteration in the activity of a gene. Modulation of expression may include, but is not limited to, gene activation and repression. Petition 870250103694, dated 12 / 11 / 2025, pp. 164 / 211 67 / 97 [000185] The term “operatively linked” or its equivalents (e.g., “operatively connected”) means that two or more molecules are positioned relative to each other in such a way that they are capable of interacting to affect a function attributable to one or both molecules or to a combination thereof. [000186] Non-covalently linked components and methods for producing and using non-covalently linked components are disclosed. The various components can take a variety of different forms, as described in this document. For example, non-covalently linked (i.e., operatively linked) proteins can be used to allow temporary interactions that circumvent one or more problems in the art. The ability of non-covalently linked components, such as proteins, to associate and dissociate allows functional association only or primarily in circumstances where such association is required for the desired activity. The connection can last long enough to allow the desired effect. [000187] A method for targeting proteins to a specific locus in an organism's genome is disclosed. The method may comprise the steps of providing a DNA localization component and providing an effector molecule, wherein the DNA localization component and the effector molecule are able to bind operatively via a non-covalent bond. [000188] A target site or target sequence is a nucleic acid sequence that defines a portion of a nucleic acid to which a binding molecule will bind, provided there are sufficient conditions for binding. [000189] The terms nucleic acid, oligonucleotide or polynucleotide refer to at least two linked nucleotides. Petition 870250103694, dated 12 / 11 / 2025, pp. 165 / 211 68 / 97 are covalently linked together. The representation of a single strand also defines the sequence of the complementary strand. Thus, a nucleic acid can also encompass the complementary strand of a single strand shown. A nucleic acid in the disclosure also encompasses substantially identical nucleic acids and complements thereof that maintain the same structure or encode the same protein. [000190] Disclosure probes may comprise a single-stranded nucleic acid that can hybridize with a target sequence under stringent hybridization conditions. Thus, nucleic acids in disclosure may refer to a probe that hybridizes under stringent hybridization conditions. [000191] Disclosure nucleic acids can be single-stranded or double-stranded. Disclosure nucleic acids can contain double-stranded sequences, even when most of the molecule is single-stranded. Disclosure nucleic acids can contain single-stranded sequences, even when most of the molecule is double-stranded. Disclosure nucleic acids can include genomic DNA, cDNA, RNA, or a hybrid thereof. Disclosure nucleic acids can contain combinations of deoxyribonucleotides and ribonucleotides. Disclosure nucleic acids can contain combinations of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine, hypoxanthine, isocytosine, and isoguanine. Disclosure nucleic acids can be synthesized to comprise non-natural amino acid modifications. Disclosure nucleic acids can be obtained by chemical synthesis methods or by recombinant methods. [000192] The nucleic acids in the disclosure, whether their complete sequence or any part thereof, may not be naturally occurring. The nucleic acids in the disclosure may contain one or more mutations, substitutions, deletions, or insertions that do not occur naturally. Petition 870250103694, dated 12 / 11 / 2025, pages 166 / 211 69 / 97 natural, making the entire nucleic acid sequence non-naturally occurring. The nucleic acids in the disclosure may contain one or more duplicated, inverted, or repeated sequences, the resulting sequence of which is not naturally occurring, making the entire nucleic acid sequence non-naturally occurring. The nucleic acids in the disclosure may contain modified, artificial, or synthetic nucleotides that are not naturally occurring, making the entire nucleic acid sequence non-naturally occurring. [000193] Given the redundancy in the genetic code, a plurality of nucleotide sequences can code for any specific protein. All such nucleotide sequences are covered in this document. [000194] As used throughout the disclosure, the term promoter refers to a synthetic or naturally derived molecule that is capable of conferring, activating, or enhancing the expression of a nucleic acid in a cell. A promoter may comprise one or more specific transcriptional regulatory sequences to further enhance expression and / or alter the spatial and / or temporal expression thereof. A promoter may also comprise distal enhancer or repressor elements, which may be located up to several thousand base pairs from the transcription start site. A promoter may be derived from sources including viruses, bacteria, fungi, plants, insects, and animals.A promoter can regulate the expression of a gene component constitutively or differentially with respect to the cell, tissue, or organ in which the expression occurs, or with respect to the developmental stage at which the expression occurs, or in response to external stimuli such as physiological stresses, pathogens, metal ions, or inducing agents. Representative examples of promoters include the T7 bacteriophage promoter, the T3 bacteriophage promoter, the SP6 promoter, and so on. Petition 870250103694, dated 12 / 11 / 2025, pp. 167 / 211 70 / 97 operator-promoter lac, the tac promoter, the SV40 late promoter, the SV40 early promoter, the RSV-LTR promoter, the CMV IE promoter, the EF-1 Alpha promoter, the CAG promoter, the SV40 early promoter or the SV40 late promoter and the CMV IE promoter. [000195] As used throughout the disclosure, the term “substantially complementary” refers to a first sequence that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to the complement of a second sequence in a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 180, 270, 360, 450, 540 or more nucleotides or amino acids, or that the two sequences hybridize under strict hybridization conditions. [000196] As used throughout the disclosure, the term substantially identical refers to a first and second sequence that are at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical in a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 180, 270, 360, 450, 540 or more nucleotides or amino acids, or with respect to nucleic acids, if the first sequence is substantially complementary to the complement of the second sequence. [000197] As used throughout the disclosure, the term variant, when used to describe a nucleic acid, refers to (i) a part or fragment of a referenced nucleotide sequence; (ii) the complement of a referenced nucleotide sequence or part thereof; (iii) a nucleic acid that is substantially identical to a referenced nucleic acid or its complement; or (iv) a nucleic acid that hybridizes under strict conditions with the referenced nucleic acid, its complement, or sequences substantially identical to it. Petition 870250103694, dated 12 / 11 / 2025, pp. 168 / 211 71 / 97 [000198] As used throughout the disclosure, the term vector refers to a nucleic acid sequence containing an origin of replication. A vector can be a viral vector, a bacteriophage, a bacterial artificial chromosome, or a yeast artificial chromosome. A vector can be a DNA or RNA vector. A vector can be a self-replicating extrachromosomal vector and, preferably, is a DNA plasmid. A vector can comprise a combination of an amino acid with a DNA sequence, an RNA sequence, or a DNA and RNA sequence. [000199] As used throughout the disclosure, the term variant, when used to describe a peptide or polypeptide, refers to a peptide or polypeptide that differs in amino acid sequence by the insertion, deletion, or conservative substitution of amino acids, but retains at least one biological activity. A variant may also mean a protein with an amino acid sequence substantially identical to a referenced protein with an amino acid sequence that retains at least one biological activity. [000200] A conservative amino acid substitution, that is, the substitution of an amino acid for a different amino acid with similar properties (e.g., hydrophilicity, degree and distribution of charged regions), is recognized in the art as typically involving a small change. These small changes can be identified, in part, by considering the hydropathic index of the amino acids, as understood in the art. Kyte et al., J. Mol. Biol. 157: 105-132 (1982). The hydropathic index of an amino acid is based on consideration of its hydrophobicity and charge. Amino acids with similar hydropathic indices can be substituted and still retain protein function. In one aspect, amino acids with hydropathic indices of ± 2 are substituted. The hydrophilicity of amino acids can also be used to reveal substitutions that would result Petition 870250103694, dated 12 / 11 / 2025, pp. 169 / 211 72 / 97 in proteins retaining biological function. Considering the hydrophilicity of amino acids in the context of a peptide allows for the calculation of the highest local average hydrophilicity of that peptide, a useful measure that has been reported to correlate well with antigenicity and immunogenicity. U.S. Patent No. 4,554,101, incorporated herein by reference. [000201] The substitution of amino acids with similar hydrophilicity values ​​can result in peptides that retain biological activity, for example, immunogenicity. Substitutions can be performed with amino acids with hydrophilicity values ​​within ±2 of each other. Both the hydrophobicity index and the hydrophilicity value of amino acids are influenced by the specific side chain of that amino acid. Consistent with this observation, amino acid substitutions compatible with biological function are understood to be dependent on the relative similarity of the amino acids, and particularly of the side chains of these amino acids, as revealed by hydrophobicity, hydrophilicity, charge, size, and other properties. [000202] As used in this document, conservative amino acid substitutions can be defined as set forth in Tables 3, 4, and 5 below. In some respects, fusion polypeptides and / or nucleic acids encoding such fusion polypeptides include conservative substitutions that have been introduced by modification of polynucleotides encoding dissemination polypeptides. Amino acids can be classified according to their physical properties and contribution to the secondary and tertiary structure of the protein. A conservative substitution is a substitution of one amino acid for another amino acid that has similar properties. Exemplary conservative substitutions are presented in Table 3. Petition 870250103694, dated 12 / 11 / 2025, pages 170 / 211 73 / 97 Table 3 - Conservative Substitutions I Side chain characteristics: Aliphatic amino acid: Nonpolar; GAPILVF: Polar - uncharged; CSTMNQ: Polar - charged; DEKR: Aromatic; HFWY: Other; NQDE [000203] Alternatively, the conservative amino acids can be grouped as described in Lehninger, (Biochemistry, Second Edition; Worth Publishers, Inc. NY, NY (1975), pp. 71-77) as set out in Table 4. Table 4 - Conservative Substitutions II Side Chain Characteristics Amino Acid Nonpolar (hydrophobic) Aliphatic: ALIVP Aromatic: FWY Sulfur-containing: M Borderline: GY Polar uncharged Hydroxyl: STY Amides: NQ Sulfhydryl: C Borderline: GY Positively Charged (Basic): KRH Negatively Charged (Acidic): DE [000204] Alternatively, exemplary conservative substitutions are shown in Table 5. Table 5 - Conservative Substitutions III Original Residue Exemplary Substitution Ala (A) Val Leu Ile Met Arg (R) Lys His Asn (N) Gln Asp (D) Glu Cys (C) Ser Thr Gln (Q) Asn Glu (E) Asp Gly (G) Ala Val Leu Pro His (H) Lys Arg Ile (I) Leu Val Met Ala Phe Leu (L) Ile Val Met Ala Phe Lys (K) Arg His Petition 870250103694, dated 12 / 11 / 2025, pp. 171 / 211 74 / 97 Original Residue | Exemplary Substitution | Met (M) | Leu | Ile | Val | Ala | Phe (F) | Trp | Tyr | Ile | Pro (P) | Gly | Ala | Val | Leu | Ile | Ser (S) | Thr | Thr (T) | Ser | Trp (W) | Tyr | Phe | Ile | Tyr (Y) | Trp | Phe | Thr | Ser | Val (V) | Ile | Leu | Met | Ala [000205] It should be understood that the polypeptides in the disclosure are intended to include polypeptides containing one or more insertions, deletions or substitutions, or any combination thereof, of amino acid residues, as well as modifications other than insertions, deletions or substitutions of amino acid residues. The polypeptides or nucleic acids in the disclosure may contain one or more conservative substitutions. [000206] As used throughout the disclosure, the term “more than one” of the amino acid substitutions mentioned above refers to 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 or more of the amino acid substitutions mentioned. The term more than one may refer to 2, 3, 4, or 5 of the amino acid substitutions cited. [000207] The polypeptides and proteins in the disclosure, whether their complete sequence or any part thereof, may not be naturally occurring. The polypeptides and proteins in the disclosure may contain one or more mutations, substitutions, deletions, or insertions that are not naturally occurring, making the entire amino acid sequence not naturally occurring. The polypeptides and proteins in the disclosure may contain one or more duplicated, inverted, or repeated sequences, the resulting sequence of which is not naturally occurring, making the entire amino acid sequence not naturally occurring. The polypeptides and proteins in the disclosure may contain modified, artificial, or synthetic amino acids that are not naturally occurring, making the entire amino acid sequence not naturally occurring. Petition 870250103694, dated 12 / 11 / 2025, pp. 172 / 211 75 / 97 [000208] As used throughout the disclosure, “sequence identity” can be determined using the BLAST engine standalone executable program to run two sequences (bl2seq), which can be retrieved from the National Center for Biotechnology Information (NCBI) FTP site, using the standard parameters (Tatusova and Madden, FEMS Microbiol Lett., 1999, 174, 247-250; which is incorporated herein by reference in its entirety). The terms identical or identity, when used in the context of two or more nucleic acid or polypeptide sequences, refer to a specific percentage of residues that are the same in a specific region of each of the sequences.The percentage can be calculated by optimally aligning the two sequences, comparing them in the specified region, determining the number of positions where the identical residue occurs in both sequences to obtain the number of matching positions, dividing the number of matching positions by the total number of positions in the specified region, and multiplying the result by 100 to obtain the sequence identity percentage. In cases where the two sequences have different lengths or the alignment produces one or more staggered ends and the specified comparison region includes only a single sequence, the residues of the single sequence are included in the denominator but not in the numerator of the calculation. When comparing DNA and RNA, thymine (T) and uracil (U) can be considered equivalent. Identification can be performed manually or using a computational sequence algorithm such as BLAST or BLAST 2.0. [000209] As used throughout this disclosure, the term endogenous refers to a nucleic acid or protein sequence naturally associated with a target gene or a host cell into which it is introduced. [000210] This disclosure provides methods for Petition 870250103694, dated 12 / 11 / 2025, pp. 173 / 211 76 / 97 introduce a polynucleotide construct comprising a DNA sequence into a host cell. By introduction is meant presenting the polynucleotide construct to the cell in such a way that the construct gains access to the interior of the host cell. Disclosure methods do not depend on a specific method for introducing a polynucleotide construct into a host cell, but only that the polynucleotide construct gains access to the interior of a host cell. Methods for introducing polynucleotide constructs into bacteria, plants, fungi, and animals are known in the art, including, but not limited to, stable transformation methods, transient transformation methods, and virus-mediated methods. [000211] In this document, the term substantially or essentially refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length that is about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more compared to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length. In another embodiment, the terms essentially the same or substantially the same refer to a range of quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length that is about the same as a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length. [000212] As used in this document, the terms substantially free of and essentially free of are used interchangeably and, when used to describe a composition, such as a cell population or culture media, refer to a composition that is free of a specified substance or source thereof, such as 95% free, 96% free, 97% free, 98% free, 99% free of the specified substance or source thereof. Petition 870250103694, dated 12 / 11 / 2025, pp. 174 / 211 77 / 97 same, or is undetectable as measured by conventional means. The term free of or essentially free of a particular ingredient or substance in a composition also means that no such ingredient or substance is (1) included in the composition at any concentration, or (2) included in the functionally inert composition, but at a low concentration. A similar meaning may be applied to the term absence of, which refers to the absence of a specific substance or source thereof in a composition. [000213] Throughout this descriptive report, unless the context requires otherwise, the words “comprehend”, “comprises” and “comprehending” will be understood as implying the inclusion of a step, element or group of steps or elements, but not the exclusion of any other step, element or group of steps or elements. In specific embodiments, the terms “include”, “have”, “contains” and “comprehend” are used synonymously. [000214] By “consisting of” is meant the inclusion, and limitation, of everything that follows the expression “consisting of”. Thus, the expression “consisting of” indicates that the listed elements are necessary or mandatory, and that no other element may be present. [000215] By “consisting essentially of” is meant the inclusion of any elements listed after the expression, and limited to other elements that do not interfere with or contribute to the activity or action specified in the disclosure for the listed elements. Thus, the expression “consisting essentially of” indicates that the listed elements are necessary or mandatory, but that no other element is optional and may or may not be present, depending on whether or not they affect the activity or action of the listed elements. [000216] The reference, throughout this descriptive report, to Petition 870250103694, dated 12 / 11 / 2025, pp. 175 / 211 78 / 97 “an accomplishment”, “some accomplishment”, “a specific accomplishment”, “a related accomplishment”, “a particular accomplishment”, “an additional accomplishment” or “an accomplishment in an additional way” or combinations thereof means that a specific feature, structure or resource described in connection with the accomplishment is included in at least one accomplishment of this disclosure. Thus, the accomplishments of the preceding phrases in various places throughout this descriptive report do not necessarily refer to the same accomplishment. Furthermore, particular features, structures or resources may be combined in any suitable manner in one or more accomplishments. [000217] The term ex vivo generally refers to activities that occur outside of an organism, such as experimentation or measurements performed on or about living tissue in an artificial environment external to the organism, preferably with minimal alteration of natural conditions. In specific embodiments, ex vivo procedures involve living cells or tissues removed from an organism and cultured in a laboratory apparatus, usually under sterile conditions, and typically for a few hours or up to about 24 hours, but including up to 48 or 72 hours or more, depending on the circumstances. In certain embodiments, such tissues or cells may be collected and frozen, and subsequently thawed for ex vivo treatment. Tissue culture experiments or procedures lasting more than a few days, using living cells or tissues, are normally considered in vitro, although in certain embodiments this term may be used interchangeably with ex vivo. [000218] The term in vivo generally refers to activities that occur within an organism. [000219] As used in this document, the terms “reprogramming”, “dedifferentiation”, “cell power enhancement” or “enhancement” Petition 870250103694, dated 12 / 11 / 2025, pp. 176 / 211 79 / 97 of developmental potency” refers to a method for increasing the potency of a cell or dedifferentiating the cell to a less differentiated state. For example, a cell with increased cellular potency exhibits greater developmental plasticity (i.e., it can differentiate into more cell types) compared to the same cell in the non-reprogrammed state. In other words, a reprogrammed cell is one that is in a less differentiated state than the same cell in a non-reprogrammed state. [000220] As used in this document, the term “differentiation” is the process by which an unspecialized (“uncommitted”) or less specialized cell acquires the features of a specialized cell, such as a blood cell or a muscle cell. A differentiated or differentiation-induced cell is one that has assumed a more specialized (“committed”) position within a cell lineage. The term “committed,” when applied to the differentiation process, refers to a cell that has progressed along the differentiation pathway to a point where, under normal circumstances, it will continue to differentiate into a specific cell type or subset of cell types, and cannot, under normal circumstances, differentiate into a different cell type or revert to a less differentiated cell type.As used in this document, the term “pluripotent” refers to the ability of a cell to form all the lineages of the body or soma (i.e., the embryo proper). For example, embryonic stem cells are a type of pluripotent stem cell that is capable of forming cells from each of the three germ layers: the ectoderm, the mesoderm, and the endoderm. Pluripotency is a continuum of developmental potencies ranging from the incompletely or partially pluripotent cell (e.g., an epiblastic stem cell or EpiSC), which is incapable of giving rise to a complete organism. Petition 870250103694, dated 12 / 11 / 2025, pp. 177 / 211 80 / 97 down to the most primitive and pluripotent cell, which is capable of giving rise to a complete organism (for example, an embryonic stem cell). [000221] As used in this document, the term “induced pluripotent stem cells” or iPSCs means that stem cells are produced from differentiated adult, neonatal, or fetal cells that have been induced or altered, i.e., reprogrammed into cells capable of differentiating into tissues of all three germ layers or dermal layers: mesoderm, endoderm, and ectoderm. The iPSCs produced do not refer to cells as they are found in nature. [000222] As used in this document, the term “individual” refers to any animal, preferably a human patient, livestock, or other domesticated animal. [000223] A pluripotency factor or reprogramming factor refers to an agent capable of increasing the developmental potency of a cell, either alone or in combination with other agents. Pluripotency factors include, but are not limited to, polynucleotides, polypeptides, and small molecules capable of increasing the developmental potency of a cell. Exemplary pluripotency factors include, for example, transcription factors and small molecule reprogramming agents. [000224] Cell culture or cell culture refers to the maintenance, growth and / or differentiation of cells in an in vitro environment. “Cell culture media”, “culture media” (singular, “medium” in each case), “supplement” and “media supplement” refer to nutrient compositions that cultivate cell cultures. [000225] “Cultivate” or “maintain” refers to the support, propagation (growth) and / or differentiation of cells outside of tissue or the body, for example, in a sterile plastic cell culture plate or flask. Petition 870250103694, dated 12 / 11 / 2025, pp. 178 / 211 81 / 97 (or coated plastic). “Cultivation” or “maintenance” may utilize a culture medium as a source of nutrients, hormones, and / or other factors useful for propagating and / or sustaining cells. [000226] The term hematopoietic stem and progenitor cells, hematopoietic stem cells, hematopoietic progenitor cells, or hematopoietic precursor cells refers to cells that are committed to a hematopoietic lineage but are capable of further hematopoietic differentiation and include multipotent hematopoietic stem cells (hematoblasts), myeloid progenitors, megakaryocyte progenitors, erythrocyte progenitors, and lymphoid progenitors. Hematopoietic stem and progenitor cells (HSCs) are multipotent stem cells that give rise to all blood cell types, including myeloid (monocytes and macrophages, neutrophils, basophils, eosinophils, erythrocytes, megakaryocytes / platelets, dendritic cells) and lymphoid lineages (T cells, B cells, NK cells).The term definitive hematopoietic stem cell, as used in this document, refers to CD34+ hematopoietic cells capable of giving rise to mature myeloid and lymphoid cell types, including T cells, NK cells, and B cells. Hematopoietic cells also include various subsets of primitive hematopoietic cells that give rise to erythrocytes, megakaryocytes, and primitive macrophages. [000227] As used in this document, the term isolate or similar refers to a cell, or a population of cells, that has been separated from its original environment, i.e., the environment of the isolated cells is substantially free of at least one component, as found in the environment in which non-isolated reference cells exist. The term includes a cell from which some or all of the components, as found in its natural environment, are removed, for example, tissue, biopsy. The term also includes a cell from which at least one, some, or Petition 870250103694, dated 12 / 11 / 2025, pp. 179 / 211 82 / 97 all components, as found in non-naturally occurring environments, for example, culture, cell suspension. Therefore, an isolated cell is partially or completely separated from at least one component, including other substances, cells, or cell populations, as found in nature or as grown, stored, or subsisted in non-naturally occurring environments. Specific examples of isolated cells include partially pure cells, substantially pure cells, and cells grown in a non-naturally occurring medium. Isolated cells can be obtained by separating the desired cells, or populations thereof, from other substances or cells in the environment, or by removing one or more other cell populations or subpopulations from the environment. As used in this document, the term purify or similar refers to increasing purity.For example, the purity can be increased to at least 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100%. [000228] As used in this document, the term coding refers to the inherent property of specific nucleotide sequences in a polynucleotide, such as a gene, cDNA, or mRNA, to serve as templates for the synthesis of other polymers and macromolecules in biological processes that have a defined nucleotide sequence (i.e., rRNA, tRNA, and mRNA) or a defined amino acid sequence and the resulting biological properties. Thus, a gene encodes a protein if the transcription and translation of the mRNA corresponding to that gene produce the protein in a cell or other biological system. Both the coding strand, whose nucleotide sequence is identical to the mRNA sequence and is usually provided in sequence listings, and the non-coding strand, used as a template for the transcription of a gene or cDNA, can be called the coding strand of the protein or other product of that gene or cDNA. [000229] A construct refers to a macromolecule or Petition 870250103694, dated 12 / 11 / 2025, pp. 180 / 211 83 / 97 A complex of molecules comprising a polynucleotide to be delivered to a host cell, in vitro or in vivo. A vector, as used herein, refers to any nucleic acid construct capable of directing the delivery or transfer of foreign genetic material to target cells where it can be replicated and / or expressed. The term vector, as used herein, includes the construct to be delivered. A vector can be a linear or circular molecule. A vector can be integrating or non-integrating. The main types of vectors include, but are not limited to, plasmids, episomal vectors, viral vectors, cosmids, and artificial chromosomes. Viral vectors include, but are not limited to, adenovirus vectors, adeno-associated virus vectors, retrovirus vectors, lentivirus vectors, Sendai virus vectors, and the like. [000230] Integration means that one or more nucleotides of a construct are stably inserted into the cellular genome, i.e., covalently linked to the nucleic acid sequence within the cell's chromosomal DNA. Targeted integration means that the nucleotide(s) of a construct are inserted into the cell's chromosomal or mitochondrial DNA at a pre-selected site or integration site. The term integration, as used in this document, further refers to a process involving the insertion of one or more exogenous sequences or nucleotides of the construct, with or without deletion of an endogenous sequence or nucleotide at the integration site. In the case of a deletion at the insertion site, integration may further comprise the replacement of the deleted endogenous sequence or nucleotide with one or more inserted nucleotides. [000231] As used in this document, the term exogenous is intended to mean that the referenced molecule or activity is introduced into the host cell. The molecule may be Petition 870250103694, dated 12 / 11 / 2025, pages 181 / 211 84 / 97 introduced, for example, by the introduction of a coding nucleic acid into the host's genetic material, either by integration into a host chromosome or as non-chromosomal genetic material, such as a plasmid. Therefore, the term, as used in reference to the expression of a coding nucleic acid, refers to the introduction of the coding nucleic acid in an expressible form into the cell. The term endogenous refers to a referenced molecule or activity that is present in the host cell. Similarly, the term, when used in reference to the expression of a coding nucleic acid, refers to the expression of a coding nucleic acid contained within the cell and not introduced exogenously.[000232] As used in this document, a “gene of interest” or “a polynucleotide sequence of interest” is a DNA sequence that is transcribed into RNA and, in some cases, translated into a polypeptide in vivo when placed under the control of appropriate regulatory sequences. A gene or polynucleotide of interest may include, but is not limited to, prokaryotic sequences, eukaryotic mRNA cDNA, eukaryotic (e.g., mammalian) genomic DNA sequences, and synthetic DNA sequences.For example, a gene of interest may encode a miRNA, an shRNA, a native polypeptide (i.e., a polypeptide found in nature) or a fragment thereof; a variant polypeptide (i.e., a mutant of the native polypeptide with less than 100% sequence identity to the native polypeptide) or a fragment thereof; an engineered polypeptide or peptide fragment, a therapeutic peptide or polypeptide, an imaging marker, a selectable marker, and the like. [000233] As used in this document, the term polynucleotide refers to a polymeric form of nucleotides of any length, whether deoxyribonucleotides or ribonucleotides or analogs thereof. The sequence of a polynucleotide is composed of four bases. Petition 870250103694, dated 12 / 11 / 2025, pages 182 / 211 85 / 97 nucleotides: adenine (A); cytosine (C); guanine (G); thymine (T); and uracil (U) for thymine when the polynucleotide is RNA. A polynucleotide can include a gene or gene fragment (e.g., a probe, a primer, an EST or SAGE tag), exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. Polynucleotide also refers to double-stranded and single-stranded molecules. [000234] As used in this document, the terms peptide, polypeptide, and protein are used interchangeably and refer to a molecule with amino acid residues covalently linked by peptide bonds. A polypeptide must contain at least two amino acids, and there is no limitation as to the maximum number of amino acids in a polypeptide. As used in this document, the terms refer to both short chains, which are also commonly referred to in the art as peptides, oligopeptides, and oligomers, for example, and longer chains, which are generally referred to in the art as polypeptides or proteins. Polypeptides include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, polypeptide variants, modified polypeptides, derivatives, analogs, fusion proteins, among others.Polypeptides include natural polypeptides, recombinant polypeptides, synthetic polypeptides, or a combination thereof. [000235] As used in this document, the term engager refers to a molecule, for example, a fusion polypeptide, capable of forming a bond between an immune cell, for example, a T cell, an NK cell, an NKT cell, a B cell, a macrophage, a neutrophil, and a tumor cell; and activating the immune cell. Examples of engagers Petition 870250103694, dated 12 / 11 / 2025, pp. 183 / 211 86 / 97 include, but are not limited to, bispecific T cell engagers (BiTEs), bispecific killer cell engagers (BiKEs), trispecific killer cell engagers, multispecific killer cell engagers, or universal engagers compatible with multiple immune cell types. [000236] As used in this document, the term specific or specificity can be used to refer to the ability of a molecule, for example, a receptor or a coupler, to selectively bind to a target molecule, as opposed to non-specific or non-selective binding. [000237] “Functional”, as used in the context of genomic editing or modification of iPSCs and differentiated non-pluripotent cells derived therefrom, or genomic editing or modification of non-pluripotent cells and reprogrammed iPSCs derived therefrom, refers to (1) at the gene level — successful knocked-in, knocked-out, knocked-down, transgenic or controlled gene expression, such as inducible or temporal expression at a desired stage of cell development, which is achieved through direct genomic editing or modification, or through “passage” via differentiation or reprogramming of an initial cell that is initially genetically modified;or (2) at the cell level — successful removal, addition or alteration of a cellular function / characteristic by means of (i) modification of gene expression obtained in said cell by means of direct genome editing, (ii) modification of gene expression maintained in said cell by means of “passage” through differentiation or reprogramming of an initial cell that is initially genetically modified; (iii) downstream gene regulation in said cell as a result of modification of gene expression that only appears at an earlier stage of development of said cell, or only appears in the initial cell that gives rise to said cell by means of differentiation or reprogramming; or (iv); Petition 870250103694, dated 12 / 11 / 2025, pages 184 / 211 87 / 97 Enhanced or newly obtained cellular function or attribute displayed within the mature cell product, initially derived from genomic editing or modification conducted on the iPSC, progenitor, or dedifferentiated cell origin. Examples [000238] The examples in this section are provided for illustration purposes only and are not intended to limit the invention. EXAMPLE 1: Genetic Engineering Methods for Hematopoietic Stem and Progenitor Cells Exemplary Method for Isolating Human Hematopoietic Stem Cells and Progenitor Cells (HSPCs) from Peripheral Blood [000239] Human CD34+ HSPCs were isolated from mobilized peripheral blood of healthy donors using an automated CliniMACS Prodigy instrument (Miltenyi Biotec) with CD34 GMP Microspheres (Miltenyi Biotec, #170-076-711) and the TS 510 program according to the manufacturer's instructions. The purity of the isolated cells was assessed by flow cytometry using CD34-AF647 (BioLegend, Clone 561, No. 343618) and CD45-PE (BioLegend, Clone HI30, No. 304008) with DAPI (BioLegend, No. 422801) as a viability dye. On the same day of isolation, the cells were frozen in CryoStor CS10 medium (STEMCELL Technologies, No. 07930). Illustrative Method for Introducing Nucleic Acids into HSPCs Using Electroporation [000240] Isolated frozen CD34+ HSPCs using the methods described above were thawed and cultured in StemSpan SFEM II medium (STEMCELL Technologies, #09655) supplemented with 100 ng / ml recombinant human stem cell factor, 100 ng / ml recombinant human Flt3 / Flk-2 ligand, and 100 ng / ml recombinant human thrombopoietin (STEMCELL Technologies Cat. Nos. 78062, 78009, and 78210.1, respectively) at 1x10⁶ cells / ml in a humidified incubator with a 5% CO₂ atmosphere at 37 °C. After 24 hours in culture, the HSPCs were subjected to electroporation. Petition 870250103694, dated 12 / 11 / 2025, pages 185 / 211 88 / 97 using the P3 Primary Cell 4D-Nucleofector X kit (Lonza, #V4XP-3032) with the EO-100 program according to the manufacturer's instructions. The electroporated cells were resuspended in culture medium at 7.5 x 10⁵ cells / ml. One day after electroporation, the HSPCs underwent a complete medium change and were cultured for a further 3 days for further downstream analyses and assays. Illustrative Method for Differentiating Erythroid from HSPCs [000241] Four days after electroporation, HSPCs were transferred to an expansion medium consisting of StemSpan SFEM II medium supplemented with 10 ng / ml recombinant human stem cell factor, 2 U / ml recombinant human erythropoietin (STEMCELL Technologies, #78007.1), 1 ng / ml human IL-3 (R&D Systems, #203-IL-010), 1 mM dexamethasone (Sigma, #D4902), and 1 mM β-estradiol (BioGems, #5022822) at a density of 2 x 10⁵ cells / ml. Every three to four days, the cells were counted, and expansion medium was added to the culture to maintain the cells at 2 x 10⁵ cells / ml. After 11 days in expansion medium, the cells underwent a complete medium change to a maturation medium composed of StemSpan SFEM II supplemented with 4 U / ml recombinant human erythropoietin and 0.5 mg / ml holotransferrin (Sigma, No. T0665) at a density of 4 to 5 x 10⁶ cells / ml. The cells were maintained in maturation medium for a further 7 days.Every three or four days, the cells were counted and maturation medium was added to the culture to maintain the cells at 4 to 6 x 10⁶ cells / ml. EXAMPLE 2: Methods for Analysis of Genetically Edited Hematopoietic Stem and Progenitor Cells Illustrative Method for Detection and Quantification of Insertions or Deletions (Indels) in HBG Gene-Edited HSPCs and Differentiated Erythroid Cells [000242] Genomic DNA (gDNA) was extracted from control HSPCs and edited for the HBG gene using the Quick-DNA Microprep kit (Zymo, Petition 870250103694, dated 12 / 11 / 2025, pages 186 / 211 89 / 97 #D3020) according to the manufacturer's instructions. The extracted genomic DNA was subjected to PCR amplification of the HBG1 / 2 genes using the Platinum™ SuperFi II PCR Master Mix (ThermoFisher, No. 12368050) according to the manufacturer's instructions using a direct primer: ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCAGTATCCTCTTGGGGG (SEQ ID NO: 24) and a reverse primer: GACTGGAGTTCAGACGTGTGCTCTTCCGATCTACCTCAGACGTTCCAGAA GC (SEQ ID NO: 25) flanking the HBG gene region of interest. [000243] PCR products were further purified using the Select-a-Size DNA Clean & Concentrator MagBead kit (Zymo, No. D4085), according to the manufacturer's instructions, followed by next-generation sequencing (NGS) library preparation using NEBNext® Ultra™ II Q5® Master Mix (New England BioLabs, No. M0544X) with NEBNext® Multiplex Oligos for Illumina® (Primer Index 96) (New England BioLabs, No. E6609S) for sample multiplexing. Libraries were pooled and sequenced in pairs on Illumina MiSeq with a depth of at least 20,000 reads per sample, according to the manufacturer's instructions. The generated FASTQ files were used as input for indel quantification using CRISPRsso2 software with the following options: -min_average_read_quality 30, -min_single_bp_quality 10, exclude_bp_from_left 15, -exclude_bp_from_right 15, -ignore_substitutions TRUE, -amplicon_min_alignment_score 60, -quantification_window_size 90. [000244] For separate indel measurement at the HBG1 locus or For individual HBG2, a pre-amplification step was added to the procedures described above using the Platinum™ SuperFi II PCR Master Mix with the following PCR primers: Direct HBG1: TCCACAGTACCTGCCAAAGA (SEQ ID NO: 26); Reverse HBG1: GCCTACCTTCCCAGGGTTTC (SEQ ID NO: 27); Direct HBG2: GGCCTAAAACCACAGAGAGTAT (SEQ ID NO: 28); and HBG2 Petition 870250103694, dated 12 / 11 / 2025, pages 187 / 211 90 / 97 reverse: CCCCACAGGCTTGTGATAGT (SEQ ID NO: 29). The Indel measurement at the individual HBG1 or HBG2 locus was determined using the methods described above. Illustrative Method for Analyzing and Quantifying Populations of HSPC and Erythroid Progenitors using Flow Cytometry [000245] Prior to erythroid differentiation, HSPCs were subjected to flow cytometry to assess their expression of stemness markers, including CD34-BV785 (BioLegend, Clone 561, #343626), CD90-APC (BioLegend, Clone 5E10, #328114), CD38-PE (BioLegend, Clone HB-7, #356604) and CD133-PE (BD, Clone 293C3, #567917), along with a viability dye Fixable Viability Stain 450 (BD, #562247). Cells analyzed during erythroid differentiation were harvested, and the cell surface was stained with the erythroid lineage markers CD235a-APC (BioLegend, Clone HI264, No. 349114) and CD71-PerCP / Cy5.5 (BioLegend, Clone CY1G4, No. 334114), along with the viability stain Fixable Viability Stain 450. Subsequently, the differentiated cells were fixed and permeabilized using the Transcription Factor Buffer Set (BD, No. 562725), followed by intracellular staining of fetal hemoglobin using HbF-PE (BD, Clone 2D12, No. 560041).Stained cells were measured using BD FACS Celesta or Agilent NovoCyte Quanteon, according to the manufacturer's instructions. Illustrative Method for Measuring the Percentage of Gamma Globin Indels Gene Expression in Differentiated HBG-Unedited and HBG-Edited HSPC Cells Using RT-qPCR. [000246] Differentiated HSPC cells were harvested and mRNA extracted using the RNeasy Mini Kit (QIAGEN, No. 74106) with column DNA digestion, according to the manufacturer's instructions (RNase-Free DNase Set, QIAGEN, No. 79254). The mRNA was reverse transcribed using the iScript™ Reverse Transcription Supermix (Bio-Rad, No. 1708841). The resulting cDNA was Petition 870250103694, dated 12 / 11 / 2025, pages 188 / 211 91 / 97 used for qPCR using the SsoAdvanced Universal Probes Supermix (Bio-Rad, No. 1725281) on the Bio-Rad CFX Opus 384 Real-Time PCR Instrument, according to the manufacturer's instructions. TaqMan probe-based assays were ordered from ThermoFisher to detect gene expression of HBG1 / 2 (Hs00361131_g1), HBB (Hs00747223_g1), HBA1 (Hs07292163_s1), and RPP30 (Hs01124518_m1). Illustrative Method for Analysis and Quantification of Differentiated Cells from HBG-Edited and Unedited HSPC Cells Using a Colony Forming Unit (CFU) Assay [000247] Four days after electroporation, control and edited HSPCs were frozen in CryoStor CS10 medium. The frozen HSPCs were used in a colony-forming unit (CFU) assay according to the manufacturer's instructions. After thawing, the cells were added to an aliquot of MethoCult™ GF+ H4435 (Enriched with H4435) (STEMCELL Technologies, No. 04445). To maximize the number of well-separated colonies to be formed, the cells were seeded at 3 densities (250, 500, and 1500 cells / well), with each density containing 3 wells replicated in a 6-well STEMvision™ SmartDish™ (STEMCELL Technologies, No. 27371). The cells were placed in a humidified incubator with a 5% CO2 atmosphere at 37 °C for 12 to 14 days. Subsequently, the total number of erythroid (BFU-E), myeloid (CFU-GM), and multipotential progenitor (CFU-GEMM) colonies was assessed by trained personnel and enumerated based on morphology.For each sample, well-separated BFU-E and CFU-GM colonies were harvested from the cultures, and genomic DNA from the harvested colonies was extracted using the QuickExtract DNA Extraction Solution (Biosearch Technologies, No. QE0905T). The remaining colonies from each of the harvested cultures were also harvested en masse, and genomic DNA was extracted using the Quick-DNA Microprep Kit. The gDNA of... Petition 870250103694, dated 12 / 11 / 2025, pages 189 / 211 92 / 97 individual colonies and mass cultures were subjected to indel detection and quantification. EXAMPLE 3: Compositions Comprising Exemplary Cas-CLOVER and HBG gRNA Pairs Result in Dose-Dependent Editing of HBG Loci in HSPCs [000248] Exemplary compositions comprising gRNA and Cas-CLOVER pairs were designed to edit BCL11A binding sites present upstream of the HBG1 and HBG2 genes in HSPCs. HSPCs were isolated and frozen according to the methods described above. The HSPCs were then thawed and cultured for 24 hours according to the methods described above. After 24 hours in culture, the HSPCs were nucleofected with mRNA encoding Cas-CLOVER gRNA pairs according to Table 6. Table 6 Cas-CLOVER and Cas-CLOVER gRNA pairs that target HBG1 OR HBG2 Cas-CLOVER CasCLOVER (pg / ml) gRNA Pairs Concentrations of gRNA pairs (pg / ml) SEQ ID NO: 39 100 Pair #1 (SEQ ID NO: 2 and SEQ ID NO: 4) 40, 200, 400 SEQ ID NO: 39 100 Pair #2 (SEQ ID NO: 6 and SEQ ID NO: 4) 40, 200, 400 SEQ ID NO: 41 100 Pair #3 (SEQ ID NO: 8 and SEQ ID NO: 4) 40, 200, 400 SEQ ID NO: 39 SEQ ID NO: 42 50 50 Pair #4 (SEQ ID NO: 10 and SEQ ID NO: 12) 40, 200, 400 [000249] Electroporated cells were resuspended in culture medium at 7.5 x 10⁵ cells / ml for four days. Four days later, the electroporated cells were harvested and genomic DNA (gDNA) was extracted according to the methods described above. The HBG genomic region encompassing the Cas-CLOVER target sites was amplified by PCR and subjected to next-generation sequencing (NGS). The small insertions and deletions (indels) induced by Cas-CLOVER editing, measured as percentages of Petition 870250103694, dated 12 / 11 / 2025, pages 190 / 211 93 / 97 modified reads relative to the total sequencing reads were quantified using the CRISPResso2 bioinformatics pipeline described above. All four gRNA pairs generated dose-dependent indels at the HBG1 and HBG2 loci in electroporated HSPCs (FIGURE 1). gRNA pairs #2, #3, and #4 generated significantly larger indels than pair #1. At a concentration of approximately 400 pg / ml, pair #3 resulted in more than 30% modified reads. [000250] This experimental procedure was repeated using additional gRNA pairs and concentrations. HSPCs were nucleofected with mRNA encoding Cas-CLOVER pairs and gRNA according to Table 7. Table 7 Cas-CLOVER and gRNA pairs that target HBG1 or HBG2 Cas-CLOVER CasCLOVER (pg / ml) gRNA Pairs Concentrations of gRNA pairs (pg / ml) SEQ ID NO: 39 200 Pair #2 (SEQ ID NO: 6 and SEQ ID NO: 4) 200, 400 SEQ ID NO: 41 200 Pair #3 (SEQ ID NO: 8 and SEQ ID NO: 4) 200, 400 SEQ ID NO: 39 SEQ ID NO: 42 100 100 Pair #4 (SEQ ID NO: 10 and SEQ ID NO: 12) 200, 400 SEQ ID NO: 42 200 Pair #5 (SEQ ID NO: 14 and SEQ ID NO: 12) 200, 400 SEQ ID NO: 42 200 Pair #6 (SEQ ID NO: 19 and SEQ ID NO: 12) 200, 400 SEQ ID NO: 41,200 Pair #7 (SEQ ID NO: 16 and SEQ ID NO: 4) 200,400 SEQ ID NO: 41,200 Pair #8 (SEQ ID NO: 18 and SEQ ID NO: 4) 200, 400 [000251] The results of this experiment are shown in FIGURE 2. gRNA pairs #2, #3, #4 and #5 demonstrated appreciable editing of the HBG loci resulting in indel percentages between approximately 20-35% and a trend of increased editing percentages at higher gRNA concentrations. gRNA pairs #6, #7 and #8 exhibited reduced levels of HBG editing compared to gRNA pairs #2, #3, #4 and #5. Petition 870250103694, dated 12 / 11 / 2025, pp. 191 / 211 94 / 97 [000252] This experimental procedure was repeated using certain gRNA pairs and Cas-Clover variants. HSPCs were nucleofected with mRNA encoding Cas-CLOVER (100 ug / ml for each variant) and gRNA pairs (200 ug / ml for each guide) according to Table 8. Table 8 Cas-CLOVER and gRNA pairs that target HBG1 or HBG2 ID do par Cas-CLOVER (esquerda e direita) Pares de gRNA 4 SpCC SEQ ID NO: 39 SaCC SEQ ID NO: 42 SEQ ID NO: 9 GGCAAGGCTGGCCAACCCAT SEQ ID NO: 11 GCAAACTTGACCAATAGTCT 4.1 SpCC SEQ ID NO: 39 SaCC-XL SEQ ID NO: 43 SEQ ID NO: 9 GGCAAGGCTGGCCAACCCAT SEQ ID NO: 11 GCAAACTTGACCAATAGTCT 9 SpCC SEQ ID NO: 39 SaCC SEQ ID NO: 42 SEQ ID NO: 15 CCCATGGGTGGAGTTAGCC SEQ ID NO: 11 GCAAACTTGACCAATAGTCT 9.1 SpCC-XL SEQ ID NO: 41 SaCC-XL SEQ ID NO: 43 SEQ ID NO: 15 CCCATGGGTGGAGTTAGCC SEQ ID NO: 11 GCAAACTTGACCAATAGTCT 9.2 SpCC SEQ ID NO: 39 SaCC-XL SEQ ID NO: 43 SEQ ID NO: 15 CCCATGGGTGGAGTTAGCC SEQ ID NO: 11 GCAAACTTGACCAATAGTCT 10 SpCC SEQ ID NO: 39 SaCC SEQ ID NO: 42 SEQ ID NO: 17 CCATGGGTGGAGTTTAGCCA SEQ ID NO: 11 GCAAACTTGACCAATAGTCT 10.1 SpCC-XL SEQ ID NO: 41 SaCC-XL SEQ ID NO: 43 SEQ ID NO: 17 CCATGGGTGGAGTTTAGCCA SEQ ID NO: 11 GCAAACTTGACCAATAGTCT 10.2 SpCC SEQ ID NO: 39 SaCC-XL SEQ ID NO: 43 SEQ ID NO: 17 CCATGGGTGGAGTTTAGCCA SEQ ID NO: 11 GCAAACTTGACCAATAGTCT 11 SaCC SEQ ID NO: 42 SpCC SEQ ID NO: 39 SEQ ID NO: 13 AAGGCAAGGCTGGCCAACCC SEQ ID NO: 3 TAGTCTTAGAGTATCCAGTG 11.1 SaCC-XL SEQ ID NO: 43 SpCC-XL SEQ ID NO: 41 SEQ ID NO: 13 AAGGCAAGGCTGGCCAACCC SEQ ID NO: 3 TAGTCTTAGAGTATCCAGTG. Petition 870250103694, dated 12 / 11 / 2025, pp. 192 / 211 95 / 97 Cas-CLOVER Pair ID (Left and Right) gRNA Pairs 11.2 SaCC SEQ ID NO: 42 SpCC-XL SEQ ID NO: 41 SEQ ID NO: 13 AAGGCAAGGCTGGCCAACCC SEQ ID NO: 3 TAGTCTTAGAGTATCCAGTG 12 SaCC SEQ ID NO: 42 SpCC SEQ ID NO: 39 SEQ ID NO: 7 AAGGCTGGCCAACCCATGGG SEQ ID NO: 3 TAGTCTTAGAGTATCCAGTG 12.1 SaCC-XL SEQ ID NO: 43 SpCC-XL SEQ ID NO: 41 SEQ ID NO: 7 AAGGCTGGCCAACCCATGGG SEQ ID NO: 3 TAGTCTTAGAGTATCCAGTG 12.2 SaCC SEQ ID NO: 42 SpCC-XL SEQ ID NO: 41 SEQ ID NO: 7 AAGGCTGGCCAACCCATGGG SEQ ID NO: 3 TAGTCTTAGAGTATCCAGTG [000253] The results of this experiment are shown in FIGURE 8. gRNA pairs 11, 11.2, 12, and 12.2 demonstrated appreciable editing of the HBG loci, resulting in index percentages between approximately 25-50%, comparable to or better than the reference ID pair 4 in Table 8. EXAMPLE 4: HBG-edited HSPCs maintain multi-lineage differentiation potential and increase HBG mRNA and HbF protein levels. [000254] HSPCs were nucleofected with 200 pg / ml of Cas-CLOVER mRNA and with 400 pg / ml of each gRNA pair #2, #3, or #4 according to the methods described above. Four days later, 1 x 10⁵ electroporated cells were isolated and gDNA was extracted essentially according to the methods described above. The remaining HPSCs were divided into two separate groups: the first group was switched to erythroid differentiation as described in the methods above; and the second group was subjected to the colony-forming unit (CFU) assay in MethoCult-based culture, essentially as described in the methods above. A. Indels via Next-Generation Sequencing (NGS) [000255] Indels induced by HBG editing of HSPCs, differentiated erythroid progenitors of edited HSPCs, and mass colonies Petition 870250103694, dated 12 / 11 / 2025, pages 193 / 211 96 / 97 cells collected at the end of the CFU assay were measured via NGS and quantified by CRISPR (Crisis-2) from cells at various time points after nucleofection, according to the methods described above. On Day 4, HSPCs exhibit robust editing at HBG gene loci, as evidenced by NGS sequencing with editing rates of approximately 40-50% of cells for all three gRNA pairs tested (FIGURE 3). The percentage of HBG-edited cells is maintained on Day 11 after erythroid differentiation, demonstrating that HBG-edited HSPCs can differentiate into erythroid progenitor cells that retain the edited HBG loci. Furthermore, bulk colonies collected at the end of the CFU assay also maintain similar editing percentages to those of HSPCs and erythroid progenitor cells, demonstrating that HBG editing is maintained after HSPCs differentiate along the erythropoiesis lineage. B. Colony Forming Unit Assay [000256] On Day 20, the absolute number of CFU cell types for HSPC control samples and for HBG-edited HSPCs using gRNA Pairs #2, #3, or #4 are shown (FIGURE 4A). The absolute number of CFU-GEMM (CFU Granulocyte / Erythrocyte / Macrophage / Megakaryocyte), CFU-GM (CFU Granulocyte / Macrophage), BFU-E (Erythroid Burst Forming Unit), and CFU-E (CFU-Erythroid) cell types remained unchanged in the CFU assay for HSPCs edited using the three HBG sgRNA pairs, compared to three controls: EP only (nucleofection / electroporation only), CC only (Cas-CLOVER mRNA only), and sgRNA only. Furthermore, the relative distribution of CFU cell types also remained unchanged between controls and HBG-edited cells using Pairs 2, 3, or 4 (FIGURE 4B), demonstrating that editing using the compositions of the present disclosure does not affect the colony-forming capabilities of multilineage HSPCs. Petition 870250103694, dated 12 / 11 / 2025, pp. 194 / 211 97 / 97 C. HBG mRNA expression in RT-qPCR-edited HSPCs [000257] HBG mRNA expression was measured by RTqPCR according to the methods described above and normalized to HBB on Days 14, 18, and 21 during erythroid differentiation. Adult blood and umbilical cord blood samples were used as negative and positive controls, respectively. Fold changes were calculated by normalizing the observed expression levels to those in the EP-only control for each of the respective time points. [000258] Increased HBG mRNA expression was observed in HSPC cells edited using HBG gRNA Pairs No. 2, No. 3, and No. 4 at all time points tested, with HBG mRNA expression increasing from Day 14 to Day 21, from about 4-fold to about 9-fold for cells edited with each of the gRNA Pairs (FIGURE 5). D. HbF protein expression levels [000259] The HbF protein was detected by intracellular flow cytometry of control cells and differentiated erythroid cells from HBG-edited HSPCs, according to the methods described above. The percentage of F cells, as defined by HbF-positive staining (HbF+), determined by intracellular flow cytometry, is plotted on the left y-axis (FIGURE 6). All three gRNA pairs demonstrated an increase in the number of HbF-positive cells compared to the EP control, with an increase range of approximately 2-fold to 5-fold in the percentage of HbF-positive cells. [000260] The median fluorescence intensity (MFI) of the HbF signal per F cell was quantified only relative to the EP control and plotted on the right y-axis (FIGURE 6). The MFI for HBG-edited F cells was higher compared to the EP control, with Pair #3 showing the highest MFI per F cell among the three gRNA pairs tested. Petition 870250103694, dated 12 / 11 / 2025, pages 195 / 211

Claims

1 / 7 Claims 1. COMPOSITION, characterized by comprising: a) a first guide RNA (gRNA) and a first fusion protein or a first polynucleotide encoding the first fusion protein comprising: a mutant Cas9 polypeptide (dCas9) or an inactivated nuclease domain thereof and a Clo051 polypeptide or a nuclease domain thereof, configured to form a complex with the first gRNA, and b) a second gRNA and a second fusion protein or a second polynucleotide encoding the second fusion protein comprising: a dCas9 polypeptide or an inactivated nuclease domain thereof and a Clo051 polypeptide or a nuclease domain thereof, configured to form a complex with the second gRNA, wherein i) the first gRNA comprises a first target sequence comprising a nucleotide sequence selected from SEQ ID NOs: 1, 5, 7, 13, 15 or 17;and the second gRNA comprises a second target sequence comprising a nucleotide sequence of SEQ ID NO: 3, or ii) the first gRNA comprises a first target sequence comprising a nucleotide sequence selected from SEQ ID NOs: 7, 9 or 13; and the second gRNA comprises a second target sequence comprising a nucleotide sequence of SEQ ID NO:

11.

2. COMPOSITION, according to claim 1, characterized in that the first gRNA comprises a first support sequence and the second gRNA comprises a second support sequence, wherein the first support sequence and the second support sequence comprise a nucleotide sequence selected from SEQ ID Petition 870250103694, dated 12 / 11 / 2025, page 196 / 211 2 / 7 NO: 20 or 21.

3. COMPOSITION, according to claim 2, characterized by: a) the first gRNA comprising a nucleotide sequence selected from SEQ ID NOs: 2, 6, 8, 16 or 18; and the second gRNA comprising a nucleotide sequence from SEQ ID NO: 4, or b) the first gRNA comprising a nucleotide sequence selected from SEQ ID NOs: 10, 14 or 19; and the second gRNA comprising a nucleotide sequence from SEQ ID NO:

12.

4. COMPOSITION, according to any one of claims 1 to 3, characterized in that the first gRNA, the second gRNA, or both the first gRNA and the second gRNA, comprise one or more chemical modifications of a ribonucleotide, a ribonucleotide base, or a phosphodiester bond.

5. COMPOSITION, according to claim 4, characterized in that one or more chemical modifications comprise at least one chemically modified phosphodiester bond.

6. COMPOSITION, according to claim 5, characterized in that at least one chemically modified phosphodiester linkage is a phosphorothioate linkage.

7. COMPOSITION, according to claim 6, characterized by comprising at least two consecutive phosphorothioate linkages at the 5'-terminus of the first gRNA, the second gRNA, or both the first and second gRNA.

8. COMPOSITION, according to any one of claims 4 to 6, characterized by comprising a 2' O-Me chemical modification at the 3'-terminus of the first gRNA, the second gRNA, or both the first and second gRNA. Petition 870250103694, dated 12 / 11 / 2025, p. 197 / 211 3 / 7 9. COMPOSITION, according to any one of claims 1 to 8, characterized in that dCas9 is derived from a Cas9 polypeptide of S. pyogenes or a Cas9 polypeptide of S. aureus.

10. COMPOSITION, according to any one of claims 1 to 8, characterized in that the C-terminal of dCas9 or its inactivated nuclease domain is joined to the N-terminal of the Clo051 polypeptide or its nuclease domain by means of a peptide linker sequence selected from GGGGS and SEQ ID NO:

23.

11. COMPOSITION, according to any one of claims 9 to 10, characterized in that the first fusion protein comprises the amino acid sequence of SEQ ID NO: 39, 41, 42 or 43.

12. COMPOSITION, according to any one of claims 9 to 11, characterized in that the second fusion protein comprises the amino acid sequence of SEQ ID NO: 39, 41, 42 or 43.

13. COMPOSITION, according to any one of claims 9 to 12, characterized in that the first polynucleotide, the second polynucleotide, or both the first polynucleotide and the second polynucleotide, are an mRNA.

14. COMPOSITION, according to claim 13, characterized in that the mRNA comprises a 5'-cap.

15. COMPOSITION, characterized by comprising: i) a first gRNA comprising a nucleotide sequence of SEQ ID NO: 2, a second gRNA comprising a nucleotide sequence of SEQ ID NO: 4, a first polynucleotide sequence encoding a first fusion protein of SEQ ID NO: 39 and a second polynucleotide sequence encoding a second fusion protein of SEQ ID NO: 39; ii) a first gRNA comprising a sequence of Petition 870250103694, dated 12 / 11 / 2025, page. 198 / 211 4 / 7 nucleotides of SEQ ID NO: 6, a second gRNA comprising a nucleotide sequence of SEQ ID NO: 4, a first polynucleotide sequence encoding a first fusion protein of SEQ ID NO: 39 and a second polynucleotide sequence encoding a second fusion protein of SEQ ID NO: 39;iii) a first gRNA comprising a nucleotide sequence of SEQ ID NO: 8, a second gRNA comprising a nucleotide sequence of SEQ ID NO: 4, a first polynucleotide sequence encoding a first fusion protein of SEQ ID NO: 41 and a second polynucleotide sequence encoding a second fusion protein of SEQ ID NO: 41; iv) a first gRNA comprising a nucleotide sequence of SEQ ID NO: 10, a second gRNA comprising a nucleotide sequence of SEQ ID NO: 12, a first polynucleotide sequence encoding a first fusion protein of SEQ ID NO: 39 and a second polynucleotide sequence encoding a second fusion protein of SEQ ID NO: 42;v) a first gRNA comprising a nucleotide sequence of SEQ ID NO: 14, a second gRNA comprising a nucleotide sequence of SEQ ID NO: 12, a first polynucleotide sequence encoding a first fusion protein of SEQ ID NO: 42 and a second polynucleotide sequence encoding a second fusion protein of SEQ ID NO: 42; vi) a first gRNA comprising a nucleotide sequence of SEQ ID NO: 19, a second gRNA comprising a nucleotide sequence of SEQ ID NO: 12, a first polynucleotide sequence encoding a first fusion protein of SEQ ID NO: 42 and a second polynucleotide sequence encoding a second Petition 870250103694, of 12 / 11 / 2025, p. 199 / 211 5 / 7 fusion protein SEQ ID NO: 42;vii) a first gRNA comprising a nucleotide sequence of SEQ ID NO: 16, a second gRNA comprising a nucleotide sequence of SEQ ID NO: 4, a first polynucleotide sequence encoding a first fusion protein of SEQ ID NO: 41 and a second polynucleotide sequence encoding a second fusion protein of SEQ ID NO: 41; or viii) a first gRNA comprising a nucleotide sequence of SEQ ID NO: 18, a second gRNA comprising a nucleotide sequence of SEQ ID NO: 4, a first polynucleotide sequence encoding a first fusion protein of SEQ ID NO: 41 and a second polynucleotide sequence encoding a second fusion protein of SEQ ID NO:

41.

16. COMPOSITION, according to any one of claims 1 to 15, characterized in that the composition is encapsulated in at least one lipid nanoparticle (LNP) comprising: about 40.75% of a compound of Formula (I) by mol, Formula (I): about 51.75% cholesterol by mol, about 5% DOPC by mol, and about 2.5% DMG-PEG2000 by mol; wherein the first polynucleotide and the second polynucleotide are an RNA molecule, and wherein the ratio of lipid to RNA molecule in at least one nanoparticle is about 120:1 (w / w).

17. COMPOSITION, according to any one of claims 1 to 15, characterized in that the composition is encapsulated in at least one LNP comprising: about 54% SS-OP by mol, about 35% cholesterol by mol, about 5% DOPC by mol, about 5% DSPC by mol and about 1% DMG-PEG2000 by mol, wherein the first polynucleotide and the second polynucleotide are RNA molecules, and wherein the lipid to RNA molecule ratio in at least one nanoparticle is about 100:1 (w / w) and the total lipid is 25 nM.

18. COMPOSITION, according to any one of claims 1 to 17, characterized by being for use in modifying an HBG1 gene, an HBG2 gene, a BCL11A gene or a combination thereof in a cell.

19. METHOD FOR MODIFYING A CELL POPULATION, characterized by comprising contacting the cell population with the composition, as defined in any one of claims 1 to 18, wherein the first gRNA forms a complex with the first target sequence and the first fusion protein, and the second gRNA forms a complex with the second target sequence and the second fusion protein, thereby generating an indel between the first target sequence and the second target sequence and producing a modified cell population.

20. METHOD, according to claim 19, characterized by the indel causing the inactivation of a BCL11A gene.

21. METHOD, according to any one of claims 19 to 20, characterized by the modified cell population exhibiting an increase of about 4 times to about 9 times in gamma globulin expression compared to an unmodified cell population.

22. METHOD, according to any one of claims 19 to 20, characterized in that the modified cell population exhibits an increased level of fetal hemoglobin (HbF) expression compared to an unmodified cell population.

23. METHOD, according to any one of claims 19 to 21, characterized in that the cells are hematopoietic stem cells and precursors (HSPCs).

24. METHOD, according to claim 23, characterized in that the HSPCs are capable of differentiating into erythroid progenitor cells.

25. CELL POPULATION, characterized by being modified according to the method as defined in any one of claims 19 to 24.

26. METHOD FOR TREATING A BETA-HEMOGLOBINOPATHY in an individual in need thereof, characterized by comprising administering to an individual the composition as defined in any one of claims 1 to 18, or the cell population as defined in claim 25.

27. METHOD, according to claim 26, characterized in the beta-hemoglobinopathy being beta-thalassemia or sickle cell anemia. Petition 870250103694, dated 12 / 11 / 2025, pp. 202 / 211